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ABSTRACT 
Each year, approximately 3-4% of the Swedish female population experiences a sexual 
assault. Only a small percentage of these women will report the assault to the police, and 
even fewer will seek medical help. This thesis is based on studies on women seeking medical 
help at the Emergency Clinic for Raped Women at Stockholm South General Hospital, in 
Stockholm, Sweden, after having been sexually assaulted. The aim of the thesis was to 
improve the knowledge about women seeking medical help after rape, explore risk the factors 
for the development of PTSD, and explore the neuroendocrinological changes in PTSD 
patients. 
Study I compared intimate partner assaults to assaults by other known assailants and to 
assaults by strangers in terms of the use of physical violence and risk of sustaining injuries. A 
retrospective review of patient files and forensic examinations from the acute visits of 690 
consecutive women showed that women who were sexually assaulted by their intimate 
partners more frequently reported physical violence (OR 4.1) than women assaulted by 
strangers (OR = 2.0) and acquaintances (OR = 1.0). Extragenital injuries showed a trend 
towards being more frequently seen after intimate partner assaults as compared to the two 
other groups. Genital injury prevalence was not related to the victim-assailant relationship.  
Study II aimed to explore the prevalence of PTSD six months after sexual assault and 
explore the potential risk factors for the development of PTSD. Two hundred and one women 
were assessed at baseline regarding mental health using self-rating questionnaires and 
followed up after six months with questionnaires, as well as a clinical interview for PTSD 
diagnosis. Thirty-nine percent of the women had developed PTSD at the six-month 
assessment, and 47% suffered from moderate or severe depression. The major risk factors for 
PTSD were having been assaulted by multiple assailants, suffering from acute stress disorder 
shortly after the assault, having been exposed to several acts during the assault, having been 
injured, having co-morbid depression, and having a history of two or more earlier traumas. 
Study III was conducted in order to adjust the concentrations of various endogenous steroids 
in Study IV for possible diurnal variation. Blood samples were taken every 4
th
 hour during a 
24-hour period in 10 premenopausal women in the follicular phase of the menstrual cycle and 
assessed regarding their concentrations of allopregnanolone, cortisol, cortisone, 11-
deoxycortisol, progesterone, 17OH-progesterone, pregnenolone, 17OH-pregnenolone, 
DHEA, androstenedione, testosterone, estrone, and estradiol. The results suggested that all 
steroids, apart from the estrogens, had a diurnal variation in the follicular phase. All steroids, 
apart from allopregnanolone, had a diurnal curve similar to that of cortisol (i.e., with a peak in 
the morning just after awakening and the lowest concentrations during the night). 
Allopregnanolone had a less steep curve, with high concentrations throughout the day and a 
peak around noon. 
Study IV assessed whether concentrations of the same endogenous steroids measured in 
Study III in the immediate aftermath of rape could predict the development of PTSD and 
depression. The study design was the same as in Study II but with a blood sample added at 
the acute visit. Low concentrations of cortisol and the ∆5 steroids (pregnenolone, 17OH-
pregnenolone, and DHEA) shortly after rape were associated with a history of earlier 
traumatization, and low allopregnanolone concentrations shortly after rape were associated 
with a psychiatric treatment history. However, there was no association between any of the 
steroids and pre-existing PTSD or the development of PTSD after six months. Results also 
suggested an association between menstrual cycle phase and the HPA axis. 
Study V assessed the sensitivity of the GABA-A receptor in 10 drug naïve patients with 
PTSD as compared to 10 healthy controls measured with saccadic eye velocity (SEV) and 
subjective ratings of sedation. SEV was measured after injections of the positive GABA-A 
receptor modulator allopregnanolone, the GABA-A receptor agonist diazepam and the 
GABA-A receptor antagonist flumazenil, each on separate occasions, and during the 
follicular phase of the menstrual cycle. The results showed that the PTSD patients were less 
sensitive to GABA-A-receptor-active substances, probably due to an acquired chronic 
tolerance to these substances caused by chronic exposure of neuroactive steroids over a long 
period of time. 
Conclusions: Sexual assaults by intimate partners are more violent and result in injuries just 
as often as assaults by strangers. However, physical injuries after sexual assaults are generally 
few and genital injuries minor. PTSD and depression, on the other hand, are common after 
sexual assaults, and an increased risk of developing PTSD is caused by a combination of 
victim vulnerability and the extent and nature of the current assault. Concentrations of 
endogenous steroids in the immediate aftermath of sexual assault (after having been adjusted 
for their diurnal variation) cannot predict the development of PTSD. However, low 
concentrations of several steroids are seen in previously traumatized women and in women 
with a psychiatric morbidity, two factors that have both been shown to increase the risk of 
developing PTSD. Finally, as a consequence of the reduced sensitivity of the GABA-A 
receptor in PTSD patients, the use of GABA-A-receptor-active compounds, such as sleeping 
pills, will be less useful for this group of patients. 
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1 INTRODUCTION 
In October 2005, all sexual assault victim care in Stockholm was centralized to the 
Emergency Clinic for Raped Women (AVK) at Stockholm South General Hospital. The 
clinic started taking care of almost all sexually assaulted women who sought help within one 
month of the assault and offered not only medical care and forensic examinations but also 
psychological help and support. The clinic garnered a large amount of attention in the media 
and soon became well-known to the population in Stockholm. Since then, the number of 
help-seeking women at the clinic has been quite stable, with about 600-700 acute visits each 
year. This makes the clinic the largest sexual assault center (SAC) in Europe and the 
possibility to perform research after sexual assaults is enormous.  
Soon after its opening, Lotti Helström, senior consultant and head of AVK, initiated clinical 
research at the clinic. In 2007, we received our first ethical permit, and I started gathering 
data for a study that was originally planned as a project within my residence training to 
become a specialist in Obstetrics and Gynecology, but eventually, it became the first study in 
this thesis. We established contact with the Crisis and Trauma Center and psychiatrist Hans 
Peter Söndergaard. Söndergaard had broad experience from working with traumatized 
patients and performing research on posttraumatic stress. A project to assess mental health in 
our patients after rape was therefore initiated in 2008. In 2010, I registered for PhD studies 
and Lotti Helström became my main supervisor. Söndergaard’s earlier research on patients 
with posttraumatic stress disorder had also suggested interesting alterations in stress steroids. 
Therefore, we initiated collaboration with Professor Torbjörn Bäckström at the Umeå 
Neurosteroid Research Center, Professor Jonas Bergquist at Uppsala University, and Mark 
Kushnir at the ARUP laboratory in Utah. We started taking blood samples from all women 
immediately after they presented at the clinic in order to see if concentrations of various 
stress steroids could predict the development of PTSD. Furthermore, the majority of 
Professor Bäckström’s earlier research had been on GABA-A receptor function in various 
diseases. As altered receptor sensitivity had been seen in patients with anxiety and work-
related stress, we began to question whether changes could also be seen in patients with 
PTSD after rape.   
In sum, this thesis is a mixture of gynecology, forensic medicine, psychiatry, and 
endocrinology, with sexual assaults being the connecting factor. 
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2 BACKGROUND 
2.1 SEXUAL ASSAULT 
2.1.1 Definitions 
In 2002, the World Health Organization (WHO) released the first Report on violence and 
Health [1]. In this report, violence was divided into three categories: self-inflicted, 
interpersonal, and collective. Sexual violence is a type of interpersonal violence and is 
defined as “any sexual act, attempts to obtain a sexual act, or acts to traffic for sexual 
purposes, directed against a person’s sexuality using coercion, harassment or advances made 
by any person regardless of their relationship to the victim, in any setting, including but not 
limited to home and work” [1,2]. This definition encompasses a broad spectrum of activities, 
ranging from violent forcible sex to sexual harassment.  
Sexual violence includes rape, which has a more narrow definition. Rape is generally defined 
as physically forced or otherwise coerced penetration of the vulva or anus using the penis, 
other body parts, or an object. Attempts to do so are defined as “attempted rape”. The term 
“sexual assault” is often defined identical as rape. 
According to the Swedish Penal Code, a rape or a sexual assault is defined as sexual 
intercourse or any kind of sexual act forced by violence, any sexual intercourse or sexual act 
with someone under the age of 15 years of age, and sexual intercourse or a sexual act with 
someone who is unable to consent [3]. 
For the purpose of this thesis, I used the definition of rape found in the Swedish Penal Code. I 
did not make any distinction between the terms “rape” and “sexual assault”, and both terms 
are used interchangeably. 
2.1.2 Prevalence 
Sexual assaults are a serious public health problem all over the world. Comparing the 
prevalence between countries is problematic because of widespread underreporting, unclear 
definitions of sexual assaults in different laws, and varying survey methodologies. A recently 
published literature review reported that the worldwide prevalence of non-partner sexual 
violence after the age of 15 years was 7%, varying between 10-20% in sub-Saharan Africa, 7-
10% in Europe, 5-13% in North America, and 3-6% in Asia [4]. However, the authors 
concluded that even though the results may reflect some true variations, differences could be 
caused by different levels of disclosure; the prevalence in some regions was based on very 
few observations, and several of the regions were affected by conflicts (making the execution 
of population-based surveys even harder). One large issue was the fact that the majority of 
the reviewed studies focused on intimate partner violence and that the questions about non-
partner sexual violence were too broad or insufficient. It has been shown that majority of all 
sexual assaults occur within an intimate partner relationship. According to the WHO´s study 
of 10 middle-and low-income countries, 6-59% of the women reported ever having 
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experienced a sexual assault by an intimate partner, and 0.3-12% reported being assaulted by 
a non-partner [5].The prevalence was higher in the poorest countries and in the rural areas as 
compared to the urban areas. 
In the US, the National Intimate Partner and Sexual Violence Survey (NISVS) found that 
18% of the women reported ever having experienced a sexual assault [6]. Furthermore, in the 
large National Co-morbidity Study, Kessler and colleagues [7] reported that the trauma 
experienced by the largest proportion of people was witnessing someone being badly injured 
or killed, both for men and women. However the risk of a women being raped was almost as 
high (Figure 1.A) 
Figure 1. Prevalence of trauma and probability of PTSD 
 
 
 
 
 
 
 
 
 
 
 
In Sweden, the number of sexual assaults reported to the Swedish police has increased 
dramatically, more than tripling during the past two decades [8]. Recently, a population-based 
report from Sweden was published [9]. In this report, 10,000 women and 10,000 men 
between the age of 17 and 74 years were asked to complete a questionnaire regarding their 
experiences of sexual, physical and psychological violence during childhood, adolescence, 
and adulthood. According to this report, 20% of the women and 5% of the men reported ever 
having been sexually assaulted. During the year studied (spring 2011-spring 2012), 3.4% of 
the women and 0.9% of the men had experienced a sexual assault. Less than 10% of the 
women and 1% of the men had sought professional help from a counselor, psychotherapist, or 
doctor and only 5% of the women and 1% of the men reported ever having reported a sexual 
assault to the police. Furthermore, both women and men who had experienced a sexual 
assault before the age of 18 years had a higher prevalence of sexual assaults in adulthood as 
compared to those who had not experienced a sexual assault before the age of 18. 
Kessler R et al. J Clin Psychiatry. 2000;61(Suppl 5):4-14.     
Kessler R et al. Arch Gen Psychiatry. 1995;52:1048-1060.
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2.1.3 Victim-assailant relationship 
In the majority of all sexual assaults, the assailant is known to the woman [2]. This is contrary 
to the myth that rapes occurs in dark alleys and are perpetrated by assailants unknown to the 
women. Even though we have now reached the 21st century, myths about “a typical rape” 
remain [10]. Although there is no legal distinction between acquaintance and stranger rapes, 
there appear to be differences in the ways in which the cases are processed in court. If the 
victim and suspect knew each other, it is easier to believe that the sexual encounter was 
consensual. Research also shows that women who are sexually assaulted by a known 
assailant are less likely to report the assault because of their fear that the legal system will not 
believe them [11]. This is clearly problematic given that the vast majority of all sexual assault 
victims know their assailants as intimate partners and that the assaults occur in private 
settings [12]. The majority of studies comparing stranger assaults to known-assailant assaults 
have not discriminated between sexual assaults by intimate partners to other known-assailant 
assaults. This has often led to the misconception that all known-assailant assaults are less 
violent than stranger assaults. The majority of studies report that sexual assaults within a 
relationship most often co-occur with physical and psychological violence, thus suggesting 
the term “intimate partner violence” (IPV). Women who have been sexually assaulted by 
their partners often suffer from repetitive assaults, and physical violence is just as common  
as sexual assaults in these relationships  [13,14]. One could therefore assume that the 
epidemiology of sexual assaults in intimate-partner relationships is uniquely different when 
compared to stranger assaults, as well as other known-assailant assaults. 
2.1.4  Mental and physical health consequences  
A growing number of studies have documented that sexual assaults in childhood, as well as in 
adulthood [9,15], are associated with a large array of both immediate and long-term 
consequences. The experience of a sexual assault correlates with several serious mental 
health problem, including anxiety disorders, depression, sleep disturbances, eating disorders, 
substance abuse, re-victimization, deliberate self-harm, and suicidal thoughts or attempts 
[16,17,18,19]. Although posttraumatic stress disorder (PTSD) is the most commonly 
researched trauma disorder (described in Section 2.2), major depression occurs at similar 
rates after trauma and frequently co-occurs with both PTSD and substance abuse [20,21,22]. 
Furthermore, sexual problems are commonly associated with a history of sexual assault [23]. 
Preliminary results from a study we conducted assessing sexual functioning after sexual 
assaults (not included in this thesis) were presented at the annual conference for the Nordic 
Association for Clinical Sexology, 2014, in Malmö, Sweden [24]. Using the Swedish version 
of the Female Sexual Function Index (FSFI) [25], we explored sexual function six months 
after sexual assaults. The FSFI has 19 questions regarding desire, arousal, lubrication, 
orgasm, satisfaction, and pain. For each question, we also added a question in which the 
subjects were asked to grade their function before the assault. Results suggested that 71% of 
the 79 completers at the six-month follow-up reported impaired sexual function as compared 
to before the assault. However, interestingly, we saw that 20% actually reported an 
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improvement, and 9% reported no difference. Impaired sexual functioning was associated 
with having a PTSD diagnosis, co-morbid depression, being un-employed, and having a 
psychiatric treatment history. The factor with the strongest association with improved sexual 
function was having a partner at the time of the assault.  
Sexual assault is also associated with physical health problems. Apart from sustaining general 
body trauma and anogenital injuries (discussed in a separate section), sexually transmitted 
infections (for updated summary of studies, see [26]), unwanted pregnancy [27], and preterm 
birth [28] have been reported. Furthermore, sexual assaults, just like IPV, have negative long-
term impacts on women´s physical health. Various kinds of chronic pain (e.g., headache and 
musculoskeletal pain) are common in women with a history of sexual assault. Studies have 
also reported an association with chronic pelvic pain and pelvic floor dysfunction [29,30,31].  
In a large Nordic cross-sectional study of women visiting gynecology clinics in Norway, 
Denmark, Finland, Iceland, and Sweden, the life-time prevalence of sexual abuse was 19-
37% [32]. The authors concluded that sexual and physical abuse was associated with 
gynecological problems but that very few of the victims were identified by their 
gynecologists. As a consequence of this, women with a history of sexual assault often had 
increased healthcare consumption. Finally, associations with a number of adverse conditions 
involving the cardiovascular, gastrointestinal, endocrine and immune systems have been 
found [31]. These associations have not been fully explained, but one hypothesis is that 
stress-related endocrine and immune reactions serve as a pathway between assaults and 
cardiovascular disease.  
It is beyond the scope of this thesis to review all outcomes associated with sexual assaults. 
Instead, I have focused on injuries and the development of PTSD after rape. 
2.1.5 Injuries 
Of all rapes reported to the Swedish police departments during 1995 and 2005, 60% of the 
cases remained unsolved, and only 12% led to prosecution [8]. The presence of anogenital 
injuries has been shown to be a major contributing factor in the various decision-making 
points from a criminal justice perspective [33]. Even though a recent study from Norway 
found that the documentation of injuries was not associated with charge filing [34], several 
studies have reported that conviction rates are higher when there is evidence of genital 
injuries [35,36,37]. The doctor is often asked to make a statement as to whether the 
intercourse was consensual or non-consensual, thereby providing support for the common 
misconception, both among the general public and among legal experts, that sexual assault is 
invariably associated with physical injuries. Studies show that consensual as well as non-
consensual intercourse can lead to genital injuries [38]. For example, one study [39] showed 
that 30% of women had genital injuries after consensual intercourse, while 32% of women 
showed signs of genital injuries after non-consensual intercourse. However, in a recently 
published Danish case-control study [40], the results suggested that the patterns of injury 
differed between the consensual and non-consensual group. Even though the overall 
 7 
frequency of at least one lesion was similar between the groups, victims of non-consensual 
intercourse more often had multiple, larger, and more complex lesions. 
Studies examining genital and non-genital injuries in female rape victims have provided 
deviating results. The prevalence of genital injury ranges from 6% [41] to 87% [42], which 
may reflect the different methods of detection being used or differences in patient 
populations, injury definition, and the experience of the examiner. Three techniques, or 
combinations of these three techniques, are being used in forensic examination: visual 
inspection, staining techniques, and colposcopy. The colposcopic technique with 
photographic capture has become a standard for evidence collection in sexual assault forensic 
examination. However, it is not routinely performed in all sexual assault centers [43] . 
Examiners using colposcopy have found an anogenital injury prevalence as high as 64% - 
87% [42,44,45]. However, the majority of published studies show a lower injury prevalence 
that more frequently ranges between 20- 40%, that injuries are small, and most often located 
in the posterior forchette of the vaginal opening [46,47,48]. Non-genital injuries have been 
found to be almost twice as common as genital injuries after sexual assaults and are most 
often seen as bruises on arms and legs. [46,47]. Furthermore, non-genital injury prevalence 
has been found to be higher when there are reports of alcohol intake prior to the assault, when 
the assault occurs outdoor, and when the victim is older [48]. 
The timeframe is crucial because genital injuries tend to disappear quickly. Maguire and 
colleagues [48] found that women examined within 72 hours of rape had significantly more 
injuries than those examined after 72 hours (40% vs. 7%, OR 3.7, 95% CI [1.05-13.09], p < 
0.05). After consensual intercourse, Astrup and colleagues [49] found that the median 
survival time for lesions was 24 hours using the naked eye, 40 hours using a colposcope, and 
80 hours using toluidine blue dye.  
As described earlier, studies comparing assault characteristics between various assailant 
groups tend to compare stranger assaults to known-assailant assaults. As we know that rapes 
committed within a relationship represent a special and uniquely different kind of assault, 
they should be separated from the rest of known-assailant assaults. After having done so, 
studies have indicated that intimate-partner assaults involve more violence and result in 
injuries more often than stranger assaults [50,51]. 
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2.2 POSTTRAUMATIC STRESS  
2.2.1 Definitions 
2.2.1.1 Definition of PTSD 
Posttraumatic stress disorder (PTSD) is a disabling psychiatric condition that can develop in 
an individual who has experienced an extremely stressful or traumatic life event, such as a 
sexual assault. A person with PTSD suffers from constant symptoms of the trauma. Persistent 
memories of the trauma can be re-lived over and over again in the form of flashbacks and/or 
nightmares. The individual tries to avoid circumstances that remind him or her of the trauma, 
such as certain places, activities, or people, sometimes leading to isolation. A person with 
PTSD also has symptoms of increased arousal that often present as sleeping disturbances, 
concentration problems, and being hyper-vigilant. Furthermore, emotional numbness can be a 
major manifestation in PTSD, causing problems experiencing and expressing loving feelings 
for someone new or someone they had previously been close to. As a consequence of all 
these symptoms, a person with PTSD may become even further isolated, lose interest in daily 
activities, and lose the capacity to work or study. Finally, a person with PTSD often feels that 
he or she has been changed by the traumatic experience. 
According to the 4
th
 Edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM- IV-TR) [52], PTSD is classified as an anxiety disorder and is characterized by 
symptoms that are divided into three clusters. The disorder follows experiencing, witnessing, 
or being confronted with events involving actual or threatened death, physical injury, or other 
threats to the physical integrity of the self or others (criterion A1). The person’s response to 
the event also has to involve intense fear, helplessness, or horror (criterion A2). For a 
diagnosis of PTSD, the B-cluster should involve at least one symptom of persistent re-
experiencing of the traumatic event, the C-cluster should involve a minimum of three 
avoidance symptoms, and the D-cluster should involve two or more symptoms of increased 
arousal. The duration of the symptoms has to be over 1 month (criterion E).  These symptoms 
sometimes lead to severe personality changes and effect important areas of functioning 
(criterion F). For a diagnosis of PTSD in the DSM IV, all six criteria have to be fulfilled (see 
Table 1). 
Symptoms can occur at any age and generally present within 3 month of the trauma, but they 
may occur years later. When the disease onset occurs at least six months after the traumatic 
event, this is called “late or delayed onset of PTSD”[53].  
Symptoms’ durations vary widely, with over 50% resolving within 3 months, but many 
victims have persistent symptoms for years. Symptom duration of less than 3 months is often 
referred to as “acute PTSD”. Symptoms persisting beyond 3 to 6 months have high 
probability of becoming chronic [54]. Symptoms are often intermittent, and relapse can 
occur. 
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Table 1.  DSM-IV-TR criteria for posttraumatic stress disorder (PTSD) 
A The person has been exposed to a traumatic event in which both of the following were present: 
 (1) The person experienced, witnessed, or was confronted with an event or events that involved 
actual or threatened death or serious injury, or a threat to the physical integrity of self or others. 
 (2) The person’s response involved intense fear, helplessness, or horror. Note: In children, this may 
be expressed instead by disorganized or agitated behavior. 
B The traumatic event is persistently reexperienced in one (or more) of the following ways: 
 (1) Recurrent and intrusive distressing recollections of the event, including images, thoughts, or 
perceptions. Note: In young children, repetitive play may occur in which themes or aspects of the 
trauma are expressed. 
 (2) Recurrent distressing dreams of the event. Note: In children, there may be frightening dreams 
without recognizable content. 
 (3) Acting or feeling as if the traumatic event were recurring (includes a sense of reliving the 
experience; illusions, hallucinations, and dissociative flashback episodes, including those that 
occur on awakening or when intoxicated). Note: In young children, trauma-specific reenactment 
may occur. 
 (4) Intense psychological distress at exposure to internal or external cues that symbolize or resemble 
an aspect of the traumatic event. 
 (5) Physiological reactivity on exposure to internal or external cues that symbolize or resemble an 
aspect of the traumatic event. 
C Persistent avoidance of stimuli associated with the trauma and numbing of general responsiveness 
(not present before the trauma), as indicated by three (or more) of the following: 
 (1) Efforts to avoid thoughts, feelings, or conversations associated with the trauma 
 (2) Efforts to avoid activities, places, or people that arouse recollections of the trauma 
 (3) Inability to recall an important aspect of the trauma 
 (4) Markedly diminished interest or participation in significant activities 
 (5) Feeling of detachment or estrangement from others 
 (6) Restricted range of affect (e.g., unable to have loving feelings) 
 (7) Sense of a foreshortened future (e.g., does not expect to have a career, marriage, children, or a 
normal lifespan) 
D Persistent symptoms of increased arousal (not present before the trauma), as indicated by two (or 
more) of the following: 
 (1) Difficulty falling or staying asleep 
 (2) Irritability or outbursts of anger 
 (3) Difficulty concentrating 
 (4) Hypervigilance 
 (5) Exaggerated startle response 
E Duration of the disturbance (symptoms in Criteria B, C, and D) is more than 1 month. 
F The disturbance causes clinically significant distress or impairment in social, occupational, or other 
important areas of functioning. 
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2.2.1.2 Definition of ASD 
The use of a diagnosis of acute stress disorder (ASD) has two purposes: to recognize 
posttraumatic stress within the first month after the trauma and to identify those victims most 
at risk of developing PTSD [55]. ASD, just like PTSD, is defined in the DSM-IV as a 
disorder that follows a trauma. Whereas PTSD reflects a disturbance that has lasted for more 
than 1 month, acute stress disorder must last for a minimum of 2 days and can only be 
diagnosed up to 1 month after the traumatic event. Acute stress disorder also differs from 
PTSD in being formulated as a dissociative response to trauma. Thus, a diagnosis of acute 
stress disorder requires at least three dissociative symptoms (criterion B) but only one 
symptom from each of the reexperiencing (criterion C), avoidance (criterion D), and arousal 
(criterion E) categories. As in PTSD, impairment (criterion F) is also necessary in an ASD 
diagnosis.  
2.2.1.3 DSM-V 
In May 2013, the American Psychiatric Association revised the PTSD and ASD diagnostic 
criteria in the 5
th
 Edition of its Diagnostic and Statistical Manual of Mental Disorders (DSM-
V) [56]. PTSD and ASD were moved from the class of anxiety disorders into a new class of 
"trauma and stressor-related disorders."  
Overall, the symptoms of PTSD are mostly the same in the DSM-V as in the DSM-IV, apart 
from some key changes. Criterion A2 (fear, helplessness, or horror just after the trauma) has 
been removed in the DSM-V because research suggested that Criterion A2 did not improve 
diagnostic accuracy [57]. Furthermore, DSM-IV Criterion C, avoidance and numbing, has 
been separated into two criteria: Criteria C (avoidance) and Criteria D (negative alterations in 
cognition and mood). By doing this, at least one avoidance symptom is required for 
diagnosis. Finally, a clinical subtype "with dissociative symptoms" was added. The 
dissociative subtype can be applied to individuals who meet the criteria for PTSD and 
experience additional depersonalization and derealization symptoms [58]. 
The changes in the classification of ASD in the DSM-V as compared to the DSM-IV are 
concordant with changes in PTSD diagnosis [59]. For a comparison, see Table 2. 
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Table 2. A comparison between DSM-IV and DSM-V diagnostic criteria for acute stress disorder 
• DSM-IV • DSM-V 
• A1 Experiencing or witnessing actual or threatened 
death, serious injury, or threat to physical integrity 
• A1 Experiencing or witnessing actual or threatened 
death, serious injury, or sexual violation, or learning that 
the event occurred to a friend or close relative 
• A2 Response involves intense fear, helplessness, or 
horror 
• Nine or more out of the following: 
• ≥ 3 Dissociative symptoms (numbing, derealization, 
depersonalization, being dazed, amnesia) 
- 2 Dissociative symptoms (numbing,  
depersonalization, amnesia) 
- 4 Intrusion symptoms (including flashbacks) 
• ≥1 Intrusion symptom - 1 Negative mood symptoms 
• ≥ 1 Avoidance symptom - 2 Avoidance symptoms 
• ≥ 1 Arousal symptom - 5 Arousal symptoms 
• Clinical distress or impairment • Clinical distress or impairment 
• Symptoms last between two days and four weeks after 
trauma 
• Symptoms last three days to one month after the event 
• Symptoms not due to physiological events, general 
medical condition, etc. 
• Symptoms not due to physiological events, general 
medical condition, etc. 
 
As the enrollment of all patients in this thesis was done before the year 2013, I have 
consistently referred to the DSM-IV definition of full PTSD and ASD in this thesis. 
 
2.2.2 Epidemiological aspects 
In the national co-morbidity study [60], Kessler reported the life-time prevalence of PTSD 
being 10% for women and half, 5%, for men. It is not clear whether this discrepancy is 
caused by women being more vulnerable or the fact that women and men experience similar 
events differently. Women are more likely than men to be molested and to subsequently 
develop PTSD after having been molested. However, women are also more prone to develop 
PTSD after a physical assault, such as mugging, despite the fact that these events are far more 
common in men. In contrast, the prevalence of PTSD after rape is actually higher in men 
(65% vs. 46%), although women are more than 10 times more likely than men to be raped; 
see Figure 1. In summary, these statistics argue against women having an increased 
vulnerability to the disorder and instead point towards the fact that certain experiences may 
involve different degrees of actual threat and physical injury and therefore result in different 
risks of developing PTSD. 
Further, Kessler reported that rape victims were at the highest risk of developing PTSD [60] 
compared to victims of other trauma types (Figure 1.B). This finding was replicated in 2005 
in a reproduction of the large co-morbidity study [61].  
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Later studies have reported that about one-third to one-half of victims will develop PTSD 
after rape [62,63,64]. Rape appears to be more likely than other traumatic events to result in 
PTSD at least in part because of specific traumatic characteristics (e.g., perceived life threat) 
that are more common in rape than in other traumatic events. However, even after adjusting 
for the traumatic circumstances around the assault, rape is still one of the traumas most 
associated with PTSD. This implies that it is something about the assault itself, in form of its 
enormously personally intrusive nature and post-assault responses that leads to the increased 
risk [65,66]. 
2.2.2.1 Risk factors for PTSD after sexual assaults 
Studies exploring risk factors for the development of PTSD after rape tend to divide the risk 
factors into three groups: pre-assault factors, assault-related factors, and post-assault factors. 
Pre-assault factors, such as prior victimization [18,67,68], have been found to be a major risk 
factor. Child sexual abuse is a risk factor for adult sexual and physical victimization and  
greater current PTSD symptoms [18,69]. Apart from its link to adult victimization, child 
sexual abuse alone is not a significant independent predictor of current post-rape PTSD 
symptomatology, but it is linked indirectly to PTSD through its relationship with adult sexual 
and physical victimization [18]. The researchers suggested a cumulative effect of child sexual 
abuse and prior adult victimization. Further, younger age [68], less education [62,65], and 
psychiatric co-morbidity [70] may be related to more severe PTSD symptoms.  
Among the assault-related factors, perceived life threat has been found to be an especially 
predictive factor for PTSD [62,68,71]. The degree of violence used during the assault has 
been found to be predictive of PTSD in some studies [62,70,72,73] but not in others [68]. 
Contradictory findings have also been reported regarding whether a completed rape, as well 
as having been exposed to several rape types during the assault, influences PTSD 
development [71] or not [68,73]. Further, the importance of the victim-assailant relationship 
has been debated. Bownes and colleagues  [73] and Ullman and colleagues  [74] found that 
victims of stranger assaults were more prone to develop PTSD, whereas Temple and 
colleagues [75] documented that sexual assault committed by a partner can be as traumatizing 
to a victim, if not more so, than sexual assault committed by a non-partner. 
Finally, several post-assault variables have been described as important in recovery after a 
sexual assault. Self-blame, loss of control, late disclosure, and avoidance coping, as well as 
unsupportive reactions and interpersonal friction with others following an assault, have all 
predicted worse PTSD symptoms at follow-up [65,68]. A large meta-analysis found that 
social support appeared to be the most important factor off all in protecting against the 
development of PTSD [76]. The prediction of PTSD through the presence of acute stress 
disorder (ASD) shortly after a traumatic event has mainly been used after non-interpersonal 
traumas [55,77,78]. After these traumas (mainly motor vehicle accidents), the positive 
predictive power of ASD was fairly high (i.e., many trauma victims who suffered from ASD 
went on to develop PTSD), but the sensitivity was only low to moderate (i.e., most of those 
who developed PTSD did not meet the initial criteria for an ASD diagnosis). This may have 
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been caused by the fact that many of those who developed PTSD had not met the initial 
dissociation criterion. Studies of ASD as a predictor of PTSD after interpersonal violence 
show a different picture. To my knowledge, only three studies have been published assessing 
ASD after interpersonal traumas [63,79,80], of which only one exclusively assessed female 
rape victims [63]. The results suggested that even though the sensitivity of ASD is higher  
after interpersonal trauma, especially after rape, the specificity of ASD is only low to 
moderate (i.e., the majority of those who did not develop PTSD had an ASD diagnosis), and 
therefore, the ASD diagnosis is of limited use. 
The majority of all studies examining risk factors for the development of PTSD after rape are 
of cross-sectional designs. These studies are often from large national probability samples or 
a group of college students. This causes some limitations, and it can be more difficult to 
identify any causal relationship between certain variables and the development of PTSD. 
Furthermore, a cross-sectional design relies on the woman’s ability to recall violent 
experiences and circumstances around the event and may cause recall bias. Thus, additional 
longitudinal studies of rape victims are important.  
2.2.3 Biological aspects 
2.2.3.1 Allostatic load 
Effectively coping with a stressful situation requires a fast response and its quick termination 
afterward [81] and the process underlying the reaction to stress is called “allostasis” [82]. The 
stress response corresponds to the severity of the stressor. Reactions to chronic or cumulative 
stressors, however, can be more pronounced or may have residual effects. The stress response 
may be insufficient, excessive, or inadequate, and the effort to recapture homeostasis may 
fail, leading to a condition called “allostatic load” [81,82]. 
The sympathetic nervous system (SNS) and the hypothalamic-pituitary-adrenal (HPA) axis 
are the major systems when the body responds to physical and emotional threat and stress. 
The SNS response is normally brief, mobilizing the acute fight-or-flight response via the 
release of norepinephrine and adrenaline. The immediate response by the SNS is followed by 
an HPA axis response that reinstates homeostasis. When this fails, it can lead to long-lasting 
adaptive changes and may be one of the biological explanations for the development of 
several diseases, such as PTSD [83].  
2.2.3.2 HPA-axis 
The majority of research on neuroendocrinological changes in PTSD has focused on 
examining the role of the HPA axis. In response to stress, corticotrophin-releasing hormone 
(CRH) is released from the hypothalamus [84], and through the hypothalamic portal vessels, 
it reaches the anterior pituitary, which subsequently releases adrenocorticotropic hormone 
(ACTH) [85], resulting in the release of the glucocorticoid cortisol from the adrenal cortex 
into the blood stream (Figure 2). The stress response is kept in check by a negative feedback 
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loop, with cortisol present in the blood stream acting on brain areas to shut down the release 
of CRH [86]. 
Figure 2. The hypothalamus-pituitary-adrenal (HPA) axis 
 
Reprint of picture from public domain without copyright restriction: 
https://embryology.med.unsw.edu.au/embryology/index.php/File:HPA_axis.jpg#filelinks 
 
It has been hypothesized that during the acute stress response after trauma, the HPA axis is 
initially hyperactive but that repetitive trauma and the constant retraumatization occurring in 
PTSD development cause alterations in the HPA axis, leading to reduced cortisol levels. This 
is a well-known phenomenon for the hypothalamic-pituitary-gonadal (HPG) axis; long-acting 
GnRH agonists are used to down-regulate the production of gonadotrophines and gonadal 
hormones. A possible explanation for the alterations in the HPA axis during chronic stress is 
the down-regulation of the CRH receptors in the pituitary. Elevated concentrations of CRH 
have been found in cerebrospinal fluid in patients with PTSD [87].  It has been assumed that 
the repeated exposure to stress-associated stimuli and subsequent cortisol release eventually 
leads to an up-regulation of glucocorticoid receptors, which in turn causes lower cortisol 
levels but at the same time a decrease in the degree of negative feedback inhibition on the 
hypothalamus and anterior pituitary, leading to increased CRH levels [81]. Although most 
research has found no differences in plasma cortisol concentrations between chronic PTSD 
patients and controls, some have shown other results. For example, 24-hour urinary cortisol 
levels were found to be lower than normal in Holocaust survivors with PTSD, even when a 
considerable amount of time had passed since the trauma [88]. However, a large meta-
analysis [89] found that after reviewing a large number of studies, lower cortisol 
concentrations in PTSD patients were found only under certain conditions. Lower 
concentrations of cortisol in PTSD were especially common when plasma or serum was used 
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for analysis, when the patients were women, and when PTSD after physical and sexual abuse 
was assessed. The same researchers therefore suggested that the deviating results were due to 
the different methodologies used. However, another meta-analysis concluded that studies 
using a low-dose of the synthetic glucocorticoid dexamethasone all pointed towards PTSD 
patients having increased feedback inhibition, leading to reduced cortisol concentrations [90]. 
The PTSD patients’ cortisol signaling capacities seem to be elevated so that lower levels of 
cortisol suppress the HPA axis. Cortisol has a huge range of effects in the body, including 
controlling metabolism, affecting insulin sensitivity, affecting the immune system, and even 
controlling blood flow [91]. 
One hypothesis regarding the development of PTSD is that the biologic stress response after 
trauma fails, resulting in a cascade of alterations. An inadequate stress response, without an 
increase of cortisol concentration, will consequently lead to a failure in the inhibition of the 
SNS, leading to increased norepinephrine concentrations after a trauma. This, in turn, may 
affect the consolidation of the memory of the incident. The memory of the event will not only 
be strongly encoded but fragmentary. The memory will also be associated with strong, 
subjective feelings of distress. Memory consolidation during an extreme stress response will 
lead to an increased risk of having intrusive recollections of the event and symptoms of 
hyperarousal. Prospective studies have suggested that low cortisol concentrations 
immediately following a trauma are related to a higher risk of developing PTSD [92,93,94] 
and that lower concentrations are seen in victims of prior trauma [95]. Only a few studies 
have been conducted on sexual assault survivors [96,97]. Resnick and colleagues found that 
female sexual assault survivors with prior assault histories had lower cortisol concentrations 
in the acute aftermath of the incident and were more likely to develop PTSD than women 
without similar histories. These results have recently been reproduced [97]. 
Studies have shown that patients with depression also have elevated CRH levels in the 
cerebrospinal fluid, but unlike patients with PTSD, they have higher than normal plasma 
cortisol concentrations, suggesting a hyperactivity of the HPA axis. Furthermore, studies 
show an insufficient suppression of corticotrophin and cortisol following a low-dose 
dexamethasone test [98,99]. This has been especially common in patients with melancholic 
depression without co-morbid PTSD. 
2.2.3.3 Endocannabinoid system 
Recently, there has been research suggesting that especially in the case of psychological 
stressors, the endocannabinoid system plays a crucial role in HPA axis regulation [100]. The 
endocannabinoid system is a neuroactive lipid signaling system that functions as a gate for 
synaptic transmitter release. It has been suggested that it is involved in the fast and the 
delayed stress systems via e.g., the disinhibition of the prefrontal output neurons that regulate 
HPA axis activity, as well as gamma-aminobutyric acid (GABA) release in the hippocampus 
[101]. Subsequently, it seems to not only be involved in the control of acute stress but also to 
influence chronic stress reactions via neuroplastic changes, as in the case of PTSD [102].  
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2.2.3.4 Neuroanatomical changes 
Recent neuroanatomical studies have identified alterations in two major brain structures, the 
amygdala and the hippocampus, in patients with PTSD. Positron-emission tomography (PET) 
and functional magnetic resonance imaging (MRI) have shown that the reactivity of the 
amygdala and frontal brain areas to trauma-related stimuli is increased and that the reactivity 
of the hippocampus, anterior cingulate, and orbitofrontal areas is decreased [103]. These 
areas of the brain are involved in fear responses. The amygdala is involved in recognizing 
stressors and sending out signals to the hypothalamus. The hippocampus plays an important 
role in the consolidation of short-term memory into long-term memory, as well as the 
termination of the stress response. Differences in hippocampal function suggest a 
neuroanatomical cause for the intrusive recollections and other cognitive problems that 
characterize PTSD [104]. Hippocampal volume has been found to be decreased in patients 
with PTSD, and even though the majority of studies have claimed that this is a result of 
stress, some others have claimed that it may be a pre-existing risk factor [103].  
2.2.4 Treatment 
Early intervention after a sexual assault is often indicated because of distress, although 
randomized controlled studies indicate that psychological debriefing in groups, rather than 
individualized approaches, may harm rather than benefit victims [105]. Instead, the key 
elements are psycho-education (including written information), a space to ventilate and feel 
safe, the reduction of shame and guilt, stabilization, and the consideration of coping 
mechanisms, sexual matters, social support, and legal support. Support in a safe environment 
can often be provided by a sexual assault center, victim support and rape crisis services, and 
general practitioners, as well as families, friends, and partners. Early interventions may also 
prevent the development of PTSD [106,107]. 
Once PTSD has developed, effective psychotherapies are available. Several PTSD treatment 
guidelines recommend trauma-focused cognitive behavioral therapy (CBT) and eye 
movement desensitization and reprocessing therapy (EMDR) as first-choice treatments 
[108,109]. CBT and EMDR are both referred to as “exposure-based” therapies, which 
confront patients with their traumatic memories. There are different CBT techniques, but 
prolonged exposure therapy is the one that has proven to be most effective. Other CBT 
techniques include cognitive processing therapy and acceptance and commitment therapy. 
Studies have shown that the effects of prolonged exposure and EMDR are comparable but 
that EMDR may be easier for some patients because it involves a faster processing of 
traumatic memories and no homework is needed [110]. Over the years, several different 
techniques have been described as useful in treating PTSD symptoms (e.g., biofeedback, 
lifespan integration, emotional freedom technique (EFT), yoga, and mindfulness). However, 
none have proven to be more effective than prolonged exposure or EMDR.  
The overall efficacy of medical treatment for PTSD is not superior to CBT or EMDR, and it 
often results in side effects. However, sometimes, medical treatment is the only option (i.e., 
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when no psychotherapy clinic is available in the area), and sometimes, it has to be added to 
an existing psychotherapy [111]. Medical treatment can be especially needed when the 
patient has a co-morbid disorder, such as depression or an anxiety disorder. Most studies 
involve antidepressants: selective reuptake inhibitors (SSRIs), serotonin-norepinephrine 
reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic 
antidepressants (TCAs), and other serotonergic agents (trazodone and nefazodone). 
Antiadrenergic drugs tested for specific problems, such as nightmares, include the alpha-1 
receptor (prazosin), the alpha-2 receptor agonists (clonidine and guanfacine), and the beta 
receptor antagonist (propanolol) for excessive arousal. Evidence supports the use of SSRIs 
and SNRIs as first-line drugs for PTSD. Recent results for prazosin and mirtazapine are also 
promising. MAOIs and TCAs are moderately effective, but they both have potentially severe 
side effects [53].  
The use of benzodiazepines in treating anxiety and insomnia in PTSD patients has been 
debated. Benzodiazepines have not been proven to be effective in treating PTSD symptoms 
[112] and are therefore not recommended [113]. Furthermore, because of reports of several 
side effects (i.e., withdrawal symptoms, interaction with alcohol, and an increased risk of 
substance abuse), as well as benzodiazepines’ lack of effect in this patient group, they have 
also been proposed as contraindicated [114]. The actual reason for these drugs’ effects is still 
unknown. The presence of extreme stress and inability to sleep after a traumatic event 
sometimes warrants treatment. The use of non-benzodiazepine sedative-hypnotics is thus 
recommended for only a short period, and traditional benzodiazepines should be used with 
caution. In an animal study in which intravenous injections of alprazolam were given in the 
immediate aftermath of stress exposure, the researchers found that this caused alterations in 
the HPA axis response, which consequently led to increased stress responses after additional 
trauma [115]. 
2.3 STEROID HORMONES 
As it has been suggested that low cortisol concentrations in the acute aftermath of rape are 
associated with the development of PTSD it would we interesting to also assess other 
endogenous steroids and neuroactive steroids. To further understand these responses and their 
effects on PTSD development, a study using validated techniques measuring serum 
concentrations of several classes of steroids in the aftermath of rape would be interesting. 
When conducting such a study, blood samples would have to be taken at the acute visit after 
the sexual assault, no matter what time of the day it is. The diurnal variation of cortisol and 
cortisone is well-described [116]. However, even though other steroids further up the 
biosynthesis pathway would probably have a similar variation, this is not clearly described in 
the literature. Allopregnanolone has been shown not to have a diurnal variation in the luteal 
phase of the menstrual cycle [117]. However, it is still possible that there is a variation in the 
follicular phase. 
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2.3.1 Steroid synthesis 
To better understand the pathophysiological changes in PTSD, one has to know about the 
steroid biosynthesis pathways. The major pathways are shown in Figure 3. All steroids are 
derived from cholesterol. The core of all steroids is 17 carbon atoms bound together to form 4 
rings. Cholesterol is the precursor of the 5 major classes of steroid hormones: glucocorticoids, 
mineralocorticoids, progestins, estrogens, and androgens. The first step is the conversion of 
cholesterol to pregnenolone, which is catalysed by the P-450 enzyme, which is under 
pituitary hormone control (ACTH or LH, depending on the tissue). From pregnenolone, 
steroid biosynthesis proceeds either through the so-called "delta-5" pathway (17-
hydroxypregnenolone, dehydroepiandrosterone (DHEA), testosterone) or through the "delta-
4" pathway (progesterone onwards). Progesterone is the starting point for mineralocorticoid 
synthesis (corticosterone, aldosterone), whereas glucocorticoids (cortisol, cortisone) are 
derived from its metabolite, 17-hydroxyprogesterone. Estrogens are formed from androgens 
(androstenedione and/or testosterone). Most reactions are irreversible (single arrow). 
Reversible reactions (double arrows) depend on cofactor availability (e.g., the 
NADP/NADPH ratio) and steroid concentrations. 
Figure 3. Major pathways of steroid biosynthesis 
 
Reprinted with permission from Frontiers in Bioscience [118]. Retrieved from: 
https://www.bioscience.org/2012/v17/af/3970/figures.htm 
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2.3.2 Neuroactive steroids 
Even though cortisol is the most studied steroid hormone in patients with PTSD (see Section 
2.2.3.2), alterations in the concentrations of other steroids along the biosynthesis pathways 
have been suggested.  
Apart from in the adrenals and gonads, steroid synthesis and/or metabolism exist in the CNS 
as well, for instance, in the glial cells. These steroids are called neurosteroids or neuroactive 
steroids, and they are either produced within the brain or pass through the blood-brain barrier 
from the periphery. They have an effect on both the peripheral and central nervous systems. 
Unlike ordinary steroids, which bind to receptors within the nucleus, neurosteroids have 
effects on neurotransmitter receptors on the cell surface. Instead of calling them 
neurotransmitters, they could be called neuromodulators. The major groups of neuroactive 
steroids are metabolites of progesterone, deoxycorticosterone, testosterone, and some other 
androgens, notably dehydroxyepiandrosterone (DHEA) and especially its sulfate (DHEAS). 
These compounds show increased concentrations both in the blood and in the brain following 
stress, and they have also been associated with sedative, anti-depressive, anxiolytic, and 
antiepileptic effects [119]. Because several of the stress steroids are potent endogenous 
positive GABA-A receptor-modulating steroids (e.g., allopregnanolone and 3alpha-hydroxy-
alpha-cortisol), they constitute a feedback loop to the CRH-ACTH production and down-
regulation of the cortisol production. 
Dehydroepiandosterone (DHEA) is mainly secreted by the adrenal cortex after ACTH 
stimulation. DHEA has anti-stress effects, blocking the effects of glucocorticoids on 
peripheral tissues and the hippocampus, and decreases anxiety [120]. Studies of DHEA and 
DHEAS in patients with stress-related psychiatric disorders are contradictory. In one study on 
sexual abuse victims with PTSD, both DHEA and DHEAS were found to be increased [121], 
while another study only found DHEAS to be increased and that DHEA did not differ 
between patients and controls [122].  Another heavily traumatized group studied is  apathetic 
refugee children [123]. Here, the results suggested a negative association between 
concentrations of cortisol and cortisone and a positive association with pregnenolone, 17OH-
pregnenolone, and DHEA with the severity of the symptoms. However, in another study of 
sexual assault victims [124] and of war veterans with PTSD [125], DHEA concentrations 
have been found to be reduced.  
Studies of DHEA in depression have been equally contradictory, but the majority of studies 
have shown elevated levels [126,127] and decreased concentrations during remission of the 
disease [128]. However, so far, no definite conclusion can be drawn regarding the impact 
of DHEA/DHEAS levels as a biomarker for depression. 
Also, alterations in the neuroactive steroid allopregnanolone have been suggested in PTSD 
patients. Allopregnanolone is a stress-related steroid that has anesthetic and anxiolytic effects, 
and it has been found to be decreased in the cerebrospinal fluid and serum in both patients 
with PTSD and depression [129,130]. 
 20 
2.4  GABA-A RECEPTOR 
The mechanism for the majority of the effects of the neuroactive steroids is through their 
effect on receptor-mediated binding to ligand-gated ion channels. The GABA-A receptor is 
the most important inhibitory receptor in the nervous system. The activation of the GABA-A 
receptor complex results in the opening of its central chloride channel, leading to the re-
polarization of the plasma membrane and the inhibition of further neuronal firing [131]. 
Activation by a positive modulator therefore causes sedation, amnesia, and ataxia, while 
activation with an inverse agonist or antagonist causes arousal, restlessness, insomnia, and 
exaggerated reactivity (Sigel and Steinmann 2012). Because the latter symptoms are all 
described in PTSD patients, it would be of interest to investigate the GABA-A receptor 
function in PTSD patients.  
Figure 4. GABA-A receptor 
 
Reprinted with permission from the Arnold Group. Retrieved from: http://www.arnoldgroup.org/Research-
GABA%20Receptor.html 
 
The receptor is a pentameric transmembrane receptor that consists of five subunits ((α1)2, 
(β2)2, and (γ2)) arranged around a central pore (see Figure 4.). There are at least 19 subunit 
compositions described in the mammalian brain. The different subunit isoforms of the 
receptor determine the receptor’s agonist affinity, chance of opening, conductance, and other 
properties. The various subunits of the GABA-A receptor also have different sensitivities to 
different drugs and endogenous GABA-A receptor-modulating steroids. 
The benzodiazepine binding site is situated between the α- and γ-subunits, and the presence 
of a γ-subunit is required for action by benzodiazepines. While the majority of GABA-
A receptors (those containing a γ-subunit combined with an α1-, α2-, α3-, or α5-subunit) are 
benzodiazepine-sensitive, there exists a minority of GABA-A receptors (containing the δ-
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subunit mainly combined with the α4- or α6-subunit) that are insensitive to classical 
benzodiazepines, but instead are hyper-sensitive to other classes of GABAergic drugs, such 
as neurosteroids and ethanol [132]. Alterations in the benzodiazepine receptor in PTSD 
patients have been suggested, and Bremner and colleagues [133] found fewer benzodiazepine 
receptors and/or a reduced affinity for receptor binding in the medial prefrontal cortex in 
patients with PTSD as compared to controls. The authors therefore suggested that alterations 
in the GABA-A (benzodiazepine) receptor in this area could be one of the explanations for 
the symptoms of PTSD. DHEAS and, to some extent, DHEA have been found to have a non-
competitive antagonistic effect on the GABA-A receptor, causing a blockage, and to some 
extent, reduced benzodiazepine binding [134]. Whether this is one of the explanations for the 
reduced effect of benzodiazepines in patients with PTSD has also been discussed. 
The GABA-A receptor subtype α4, β, δ is hypersensitive to the positive GABA-A receptor-
modulating steroid allopregnanolone, while it is subsequently insensitive to benzodiazepine. 
Flumazenil, on the other hand, is known to change its action from being a benzodiazepine 
antagonist or inert compound to being an agonist with a benzodiazepine-like effect on its own 
in GABA-A receptor subtype α4, β, δ. Therefore, the three drugs allopregnanolone, 
diazepam, and flumazenil are suitable for use in challenge tests to bring to light whether there 
are changes in GABA-A receptor sensitivity and relate the effect of compounds to possible 
changes in GABA-A receptor subtypes in a disorder. 
In a previous study of female patients with burn-out syndrome, the authors saw an increased 
sensitivity to allopregnanolone and a changed action of flumazenil suggesting an up 
regulation of GABA-A receptor subtype α4, β, δ, [135] in this group of patients. In another 
study, providing increasing doses of intravenous diazepam to patients with a panic disorder 
[136], results suggested subsensitivity of the GABA-benzodiazepine receptor complex in this 
patient group. In both mentioned studies, saccadic eye velocity (SEV) was used as an 
outcome measure. This technique is a validated and objective way of estimating sensitivity to 
GABA-A receptor drugs in the neural circuits controlling the saccade, and it has been used by 
Bäckström and colleagues in several studies [137,138,139,140]. To our knowledge, the SEV 
technique has not before been used before in investigating the GABA-A receptor complex in 
patients with PTSD.  
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3 AIMS OF THE THESIS 
 
The overall aims of this thesis were to improve the knowledge about women seeking medical 
help after rape, explore risk factors for the development of PTSD after rape, and explore 
neuroendocrinological changes in patients with PTSD. 
 
Specific aims were as follows: 
Study I To address differences in intimate-partner 
assaults compared to other known-assailant 
assaults and to sexual assaults by strangers.  
Study II To explore the prevalence of PTSD six 
months after sexual assault. 
 To explore whether it is possible to identify 
those women at the highest risk of 
developing PTSD after a sexual assault. 
Study III To explore whether endogenous steroids 
have a diurnal variation in the follicular 
phase of the menstrual cycle. 
Study IV To explore whether the concentrations of 
endogenous steroids in the immediate 
aftermath of rape can predict the 
development of PTSD and depression. 
Study V To explore possible differences in the 
GABA-A receptor sensitivity in patients 
with PTSD compared to healthy non-
traumatized controls. 
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4 METHODS 
4.1 SETTING 
All studies were conducted on female patients and controls, and all patients were recruited 
from the Emergency Clinic for Raped Women at Stockholm South General Hospital 
(Södersjukhuset), Stockholm, Sweden. The Emergency Clinic for Raped Women opened in 
October 2005 within the Obstetrics and Gynecology Department and about 600-700 women 
are seen every year. Women who have been referred from other healthcare clinics, 
emergency departments, and the police, as well as those presenting themselves, are met at the 
clinic. All sexual assault victim care in Stockholm is centralised to the Emergency Clinic for 
Raped Women, and the clinic is open 24 hours a day. The victims are offered medical and 
forensic examination within one month after the sexual assault. About 65% of the women 
have reported their assault to law enforcement. However, this is not mandatory for care. 
4.2 STUDY DESIGNS 
Different designs and methods have been used, depending on the purpose of the study. An 
overview of designs and participants is presented in Table 3.  
Table 3. Overview of study designs 
Study Design Inclusion criteria No. of studied 
participants 
I Retrospective 
observational study 
Consecutive patients from the Emergency Clinic for 
Raped Women. 
503 
II Prospective longitudinal 
study 
Patients seeking help at the Emergency Clinic for 
Raped Women,  > 18 years old,  
literate in Swedish 
201 
III Observational study Healthy, non-traumatized, drug-naïve women, 
18-40 years old 
10 
IV Prospective longitudinal 
study 
Same as Study II 108 
V Explorative study 
 
Patients: Drug-naïve women, 18-40 years old, with 
PTSD 6 months after sexual assault.  
Controls: Drug-naïve, non-traumatized women, 18-
40 years old, without PTSD. 
12 patients 
16 controls 
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Study I was a retrospective study of patient files and forensic examinations from consecutive 
patients seeking acute medical help after sexual assault during a period of 13 months between 
2007 and 2008. Victim-assailant relationships were assessed regarding their association with 
injuries and reported violence. 
Study II was a prospective, longitudinal follow-up study exploring whether certain variables 
measured at the acute visit and at the two-week follow-up could predict the development of 
PTSD at the six-month assessment. Women were asked for consent at the two-week follow-
up. The study started in February 2009 and was completed in June 2012. Participants were 
asked to fill out a number of self-rating questionnaires at the two-week and six-month follow 
ups, as well as to participate in a clinical interview at six months for the diagnosis of PTSD. 
Study III was an explorative observational study regarding the diurnal variation of a battery 
of endogenous steroids in the follicular phase of the menstrual cycle. This study was 
conducted so that blood samples taken at various hours of the day in Study IV could be 
adjusted for their possible diurnal variations. Blood samples were drawn every 4
th
 hour over 
24 hours.   
Study IV was a part of Study II and was started in April 2010 and completed in June 2012. 
The study had the same design as Study II, but with a blood sample added at the acute visit. 
When the women were asked for written consent at the two-week follow-up, blood samples 
from consenting women were stored. Blood samples were destroyed if the women did not 
consent. If the women came back for the six-month assessment, the blood sample from the 
acute visit was analyzed regarding steroid concentrations and assessed to determine whether 
they could predict the development of PTSD or depression at six months. 
Study V was an explorative study of patients diagnosed with PTSD at the six-month 
assessment in Study IV. The PTSD patients were compared with non-traumatized controls 
without PTSD regarding the sensitivity of the GABA-A receptor. Challenges with diazepam, 
flumazenil, and allopregnanolone were performed on three separate occasions, and the effects 
were measured in saccadic eye velocity (SEV) and subjective ratings of sedation (VAS). The 
study was started in April 2012 and was completed in March 2013. 
4.3 PARTICIPANTS 
In Study I, 690 women sought help at the clinic during the study period. After excluding 
those cases with too much incomplete information in the data files (n = 21), those in which 
the relationship to the assailant was not documented (n = 3), and those who were incorrectly 
registered as emergency visits, we obtained 655 included patients. Of these 655 cases, 17% (n 
= 114) were defined as single-stranger assaults, 43% (n = 287) as acquaintance assaults, and 
16% (n = 102) as intimate partner assaults. This resulted in a final sample size of 503 
patients. The mean age among the women was 25 years (range 11-95), and 25% were under 
the age of 18 at the time of the sexual assault. 
 27 
A flow diagram of participants in Studies II, IV, and V is shown in Figure 5. Because the 
blood sampling started approximately one year after the start of Study II, the number of 
participants included in Study IV was lower. Thus, all patients in Study IV were also included 
in Study II. The inclusion criteria for both Study II and IV were being over the age of 18 
years old and literate in Swedish. Women were excluded if they were believed to be unable to 
provide informed consent (e.g., mental retardation or severe mental illness).  
Figure 5. Flow diagram of study population in Studies II, IV, and V 
 
Participants in Study III were all non-traumatized controls who were recruited through 
advertisement. The inclusion criteria were being between 18 and 40 years old, not taking any 
hormonal contraceptives or daily medication, and being physically and mentally healthy. All 
blood sampling had to be performed in the follicular phase of the menstrual cycle. 
Patients included in Study V were recruited from the six-month assessment in Study IV and 
were all diagnosed with PTSD according to the SCID interview. A total of 12 patients with 
PTSD were recruited, of which 10 were planned for each of the three challenges. Patients 
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N = 69
PTSD
N = 12
Controls
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were compared to 16 controls, of which 10 were planned for each challenge. The inclusion 
criteria for both patients and controls consisted of being 18-40 years old, having fairly regular 
menstruations, not taking any hormonal contraceptives, and being drug-naïve regarding 
antidepressants, anxiolytics, and sedatives. Furthermore, all participants were excluded if they 
had a history of psychosis, major or bipolar depression, alcohol or substance abuse, 
neurological disease, endocrine disease or polycystic ovarian syndrome (PCOS) or if they 
were pregnant or planning on becoming pregnant within three months after the last challenge. 
At the time of the challenge, participants had to be in the follicular phase of the menstrual 
cycle and not have consumed any alcohol in the past 72 hours. 
4.4 MEASURES AND DATA COLLECTION 
An overview of the measures used in each study is presented in Table 4. 
Table 4. Overview of measures 
Study Measures 
Study I Self-reports 
Forensic examinations 
Study II BDI, SASRQ, PDS at two weeks follow-up 
SCID-I, BDI, SASRQ at six months follow-up 
Study III SCID-I, BDI, SASRQ 
Study IV Same as Study II  
+ Blood sample from acute visit 
Study V SEV, VAS, SCID-I, BDI, ASI, PSS, STAI, 
SADS 
 
4.4.1 Victim and assault characteristics 
In Studies I, II, and IV, all data on assault and victim characteristics were collected from the 
clinics’ structured data files and findings from the forensic examination at the acute visit. 
Data on victim and assault characteristics were therefore based on the woman’s self-report, 
while data on injuries were based on the physician’s findings.  
The victim-assailant relationships were defined as intimate partner (husband/cohabiter, 
partner, ex-partner), family member (other than intimate partner), acquaintance (an assailant 
known by the woman but not as an intimate partner or family member), stranger (single 
assailant not known by the woman), group (more than one assailant,) or uncertain (the victim 
had amnesia and could not recall).  
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The different types of assaults were defined as vaginal, oral, or anal penetration (with penis, 
hand, or foreign object) or a combination of the three. Alternatively, an assault was defined as 
other when no penetration was involved but other kinds of touching or kissing had occurred 
(involving the genitals or body parts). 
Violence was defined as hitting, kicking, holding, attempts of strangulation, or by other 
means. In Study I, if two or more types of violence were used, the violence was defined as 
multiple violence. In Studies II and IV, the violence was defined according to the NorVald 
Abuse Questionnaire [141] as none, mild (hitting, smacking your face, holding you firmly), 
moderate (hitting with fist(s) or hard object, kicking, pushing violently), or severe (threat to 
life, strangulation, showing weapon or knife).  
Genital and non-genital injuries were defined according to a modified version of the TEARS 
system [45] when Tears (breaks in tissue including fissures, cracks, cuts, and lacerations), 
Ecchymoses (skin or mucous membrane discolorations, known as bruising), Abrasions (skin 
excoriations), Redness (erythemous skin), Swelling (oedematous tissues) or Several of these 
(more than one of the mentioned injuries) were observed, and the occurrence of each was 
coded as yes/no.  
Further, information on influence of alcohol during the assault was solely based on the 
woman’s own report and was not quantified in most of the cases. In Study I, a prior assault 
history was based on the women’s answer to the question “Have you ever before been 
sexually assaulted?” In Studies II and IV, prior sexual assault history was established through 
the Posttraumatic Stress Diagnostic Scale (defined below). Finally, the time lapse between 
the sexual assault and the acute visit was defined as within 72 hours (< 72hrs) or later than 72 
hours (> 72hrs).  
4.4.2 Psychometrics 
The PTSD Module of the Structured Clinical Interview for DSM-IV (SCID-I) was used in 
Studies II-V to establish current PTSD status. In Studies II and IV, the interview was used at 
the six-month assessment. In Study III, the interview was used to establish the absence of 
PTSD in the non-traumatized controls, and in Study V, to establish full PTSD in the included 
patients and the absence of PTSD in the controls. The SCID-I is a widely used structured 
clinical interview, and a diagnosis of full PTSD was made using the DSM IV-TR (i.e., when 
clusters A and F were fulfilled). 
The Beck Depression Inventory (BDI) [142] was used both at the two-week and six-month 
follow-ups in Studies II and IV.  It was also used in Studies III and V to exclude depression 
in both patients and controls. The inventory has 21 items measuring depressive mood and 
vegetative symptoms of depression. The cut-off points for the sum scores were 0-9 (no 
depression), 10-16 (mild depression), 17-29 (moderate depression), and scores ≥30 (severe 
depression).  
The Posttraumatic Stress Diagnostic Scale (PDS) was used in Studies II and IV at the two-
week follow-up to assess PTSD symptom scores (0-51), pre-existing PTSD, and lifetime 
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histories of traumatic events [143]. Pre-existing  PTSD was diagnosed at baseline when the 
respondent in PDS part 1, reported having been exposed to or having witnessed a traumatic 
event that, according to PDS part 2, involved threat to life or physical integrity and, according 
to PDS part 3, reported having at least 1 re-experiencing symptom, more than 2 avoidance 
symptoms, and more than 1 arousal symptom, as well as having a symptom duration over 1 
month and, that the symptoms according to PDS part 4 also caused impairment in the 
respondent’s daily life in at least one area. 
The Stanford Acute Stress Reaction Questionnaire (SASRQ) [144] was used in Studies II 
and IV, mainly for diagnosis of ASD at the two-week follow-up. The SASRQ is a 30-item 
self-report instrument with 3 additional questions relevant to the diagnosis of ASD, including 
a description of the event, how disturbing it was, and how many days the individual 
experienced the worst symptoms for. The instrument can be used as a Likert-type scale (0-5) 
or dichotomously (0-2: 0, 3-5: 1) to test for the presence of a symptom. The questionnaire 
was also used as a total score (adding all items) for measuring PTSD symptom severity at the 
two-week and six-month assessments in Studies II and IV and during inclusion in Studies III 
and V.  
In Study V, the Anxiety Sensitivity Index (ASI), the Panic Symptom Scale (PSS), the State-
Trait Anxiety Inventory (STAI), and the State Anxiety and Discomfort Scale (SADS) were 
used before the start of each challenge and at home 24 hours after each challenge. SADS 
ratings were also taken throughout the challenge at 5, 13, 18, 25, 30, 45, 60, 120, and 180 
minutes. 
The Anxiety Sensitivity Index (ASI) measures the fear of panic or anxiety [145]. The overall 
score ranges from 0-64, and a mean score of 19.1 has been reported for a normal population 
[146]. 
The Panic Symptom Scale (PSS) is a 19-item questionnaire regarding different symptoms of 
panic on a scale from 0 (not at all) to 4 (extreme) [147]. 
The State-Trait Anxiety Inventory (STAI) has a total score of 20 to 80 points. A total score 
below 40 indicates low anxiety, between 40 and 59 indicates moderate anxiety, and 60 or 
more indicates a severe state of anxiety [148]. 
The State Anxiety and Discomfort Scale (SADS) ranges from 0 (no discomfort) to 5 (worst 
imaginable discomfort) and measures changes in anxiety level when used repeatedly. 
4.4.3 Steroid analysis 
Allopregnanolone concentrations in Studies III-V were analyzed at the Umeå Neurosteroid 
Research Center (UNC) in Umeå, Sweden. For a more detailed description of the analyses, 
see [140]. Briefly, the samples (0.4 ml) were extracted with diethyl ether (Merck KGaA, 
Darmstadt, Germany). Allopregnanolone was separated from cross-reacting steroids with 
celite chromatography. Allopregnanolone was measured via Radioimmunoassay (RIA) using 
a polyclonal rabbit antiserum raised against 3-hydroxy-20-oxo-5-pregnan-11-yl-
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carboxymethyl-ether coupled to bovine serum albumin, provided by RH Purdy (The Scripps 
Research Institute, La Jolla,CA,USA) [149]. 
In Studies III and IV, the LC-MS/MS technique was used for analyzing concentrations of 
the glucocorticoids (cortisol, cortisone, 11-deoxycortisol), androgens (androstenedione, 
testosterone, DHEA), pregnenes (pregnenolone, 17OH-pregnenolone), progestins 
(progesterone, 17OH-progesterone), and estrogens (estrone, estradiol). Analyses were 
performed at the ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, 
USA. For further details, see [123]. The progesterone concentrations were only used in order 
to identify those women being in the luteal phase of the menstrual cycle. 
4.4.4 Saccadic Eye Velocity (SEV) 
In order to address the research question in Study V, saccadic eye velocity (SEV) was used to 
assess the sensitivity of the GABA-A receptor in patients with PTSD as compared to healthy 
non-traumatized controls.  
SEV was measured using a non-invasive videonystagmographic device (Ulmer VNG, Atos 
Medical AB®). The device has an open mask (Visio 50) for measuring rapid eye movements, 
with a camera that privides binocular analysis. The model allows unlimited calibration in 
horizontal movements and +90 / -20⁰ vertically, and it has an accuracy of 0.1⁰. The camera 
sensor is mounted on a rigid helmet. Before the start of the study, the camera sensor was 
adjusted so that it was positioned several centimeters from the eyes, at the level of the tip of 
the nose, and pointed up towards the pupil in mid-position. The target was at a distance of 
115 cm from the eye and consisted of a white light on a black background. Participants were 
instructed to watch the white light and try not to anticipate where the next target would be. 
Calibration was achieved by asking the participant to fixate on targets at 20⁰ and 30⁰ to the 
right and left, as well as above and below the center before each series of measurements. 
Recalibration minimized error due to head movements. After calibration, measurements were 
conducted using a target moving rapidly back and forth in the horizontal plane from the left 
of center to the right of center at a constant velocity. The subject was asked to move the eye 
to the new point and fixate on that. The speed of the eye movement in degrees/second was 
calculated by a computer. Saccades of 20⁰ were used in this study. Eye position data were 
stored and displayed on the computer, and data from both eyes were combined. The peak 
velocity was calculated and displayed for each saccade.  
SEV was measured before and after injections of three separate substances. The challenges 
with diazepam (a GABA-A receptor agonist), flumazenil (a benzodiazepine antagonist at the 
GABA-A receptor), and allopregnanolone (a positive GABA-A receptor modulator), were 
performed in the mentioned order, and all were performed at separate occasions usually with 
1 month in between, but always at a minimum of 3 days in between. After the injection, SEV 
and sedation were measured after 5, 13, 18, 25, 30, 45, 60, 120, and 180 minutes. 
4.4.5 Visual Analogue Scale (VAS) 
The sensitivity of the GABA-A receptor in the PTSD patients compared to the controls in 
Study V was also measured by assessing the participants’ subjective ratings of sedation 
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during the challenges. This was done by using a visual analogue scale (VAS) [150]. The scale 
measured from 0 to 10, where 0 represented the complete absence of sleepiness and 10 
represented nearly falling asleep. The ratings were made at baseline, as well as at the same 
time points as the saccadic eye measurements. 
4.5 METHODS OF ANALYSIS 
An overview of statistical methods used in each study is shown in Table 5. In all studies, a 
statistical significance was considered when p-value was <0.05. 
Table 5. Overview of methods of analysis  
Study number  I II III IV V 
Method Pearson’s chi-square test X X  X X 
 Fisher’s exact test X     
 Independent T-test  X    
 Logistic regression X X  X  
 Repeated measures ANOVA   X  X 
 Mann-Whitney U test    X X 
 Bivariate correlations   X X  
Package SPSS 20.0 X X    
 SPSS 22.0   X X X 
 
 
In Study I, Pearson’s chi-square test or Fisher’s exact test were used to compare assault and 
victim characteristics between the three assailant groups. The three assailant groups were 
analyzed regarding their associations with the three main outcomes (multiple violence, extra-
genital injuries, and genital injuries) using logistic regression. In a multivariable model, 
associations were adjusted for age, ethnicity, type of assault, influence of alcohol, and time 
lapse between assault and examination. 
In Study II, differences between the PTSD group and the non-PTSD group were analyzed 
using Pearson’s chi-square test for categorical variables and independent t-test for continuous 
variables. A multivariable regression model was conducted to assess possible risk factors for 
the development of PTSD. First, the results from the psychometrics used at the two-week 
follow-up were examined for their association with the development of PTSD. Second, 
victim characteristics and, last of all, assault characteristics were examined for their 
association with the development of PTSD. Significant factors from each of the three models 
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were then simultaneously inserted into a final model predicting PTSD. In the final model pre-
existing PTSD was also adjusted for. 
In Study III, potential diurnal variations in the endogenous steroids were assessed by using 
repeated-measures ANOVA to establish possible within-subject variations, and the bivariate 
correlations between the steroids were analyzed using Spearman’s correlation. 
In Study IV, steroid concentrations were first adjusted for their diurnal variation, as 
established in Study III. This was done the following way: First, the mean and standard 
deviation of the steroids for each time interval were calculated in Study III. The 
concentrations of each steroid in the acute blood samples were then normalized according to 
their diurnal variations. This was done by calculating z-scores for each sample according to 
the mean and standard deviation for each steroid and time interval among the healthy controls 
in Study III (z = (x-μ)/σ, where x = individual sample value, μ = the mean of the time interval 
in the controls, and σ = the standard deviation of the mean samples in that time interval). The 
z-scores were then used when exploring differences in the serum concentrations of the 
steroids between the patients who developed PTSD and the group that did not. Pearson’s chi-
square test for categorical variables and the Mann-Whitney U test for continuous variables 
were used when comparing the two groups. The relationships between the steroid 
concentrations, PTSD, and depression at both the two-week and the six-month follow-up, 
prior assault history, and psychiatric treatment history were also analyzed using bivariate 
correlations, as well as multivariable logistic regressions.  
In Study V, differences in baseline demographic data, allopregnanolone concentrations, 
psychometrics, and sedation between patients and controls were calculated with the Mann-
Whitney U test. SEV and self-rated sedation were calculated in terms of the difference from 
the baseline at each time point (i.e., delta degrees/s and delta sedations scores). The SEV 
parameters were analyzed after the three injections using analyses of variance (ANOVA) 
with repeated measures.  
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5 ETHICAL CONSIDERATIONS 
Several ethical aspects were taken into account in the studies included in this thesis. 
First, as all studies were conducted on humans, they were all conducted in accordance with 
the Helsinki declaration. This means, among other things, that the well-being of the 
individual was more important than all other aspects of the studies. 
All five studies were approved by the Regional Ethics Committee at Karolinska Institutet, 
Stockholm, Sweden. Reference numbers: 2007/1265-31/5, 2008/759-31+ 2009/284-32/1 
(supplement), 2011/851-31/3, and 2011/852-31/3 + 2012/492-32 (supplement). 
Participants in Study I were not asked for consent, because this retrospective review of 
patient files and forensic examinations was considered part of the qualitative monitoring of 
the clinic. However, all data were anonymized, and all analyses were performed in 
anonymized datasets. 
Participants in Studies II-V were all given written information about the study before they 
were asked for informed consent. They were informed about their participation being entirely 
voluntarily and that at any time and for any reason, they could leave the study without any 
consequences for their future care. They were also informed that all their personal 
information would be handled confidentially. To ensure the participants’ anonymity, the 
baseline, as well as the follow-up questionnaires, interviews, data from challenges, and blood 
analyses, were coded with ID numbers and stored in a locked room. The key to the ID 
numbers was only available to the responsible study researchers. Because it could be ethically 
questionable to include patients in the emergency room directly after a sexual assault, all 
participants were informed and asked for consent at the follow-up appointment held after 10-
14 days. Because Study IV, aimed to explore the concentrations of endogenous steroids in the 
immediate aftermath of rape, we obtained ethical approval to take blood samples at the acute 
visit, but the women were not asked for written consent until the next visit. If the women did 
not consent, their blood samples were destroyed. 
Off course, it could be ethically questionable to perform studies on women who had recently 
experienced sexual assaults. The patients were in a vulnerable position, and many were 
affected by shock and anxiety. However, I believe that if everything possible is done to 
minimize the impact of the study on the patient’s physical, mental, and social integrity and 
the patient is fully informed and given the reason for the study, it can be justified. I also 
believe that addressing one’s feelings through answering a questionnaire or interview and the 
extra attention given to the participant within the study can actually be helpful.  
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6 RESULTS 
This section is a summary of the results of the five studies in this thesis. For a complete 
presentation, all four studies are found at the end of the thesis. 
6.1 STUDY I 
6.1.1 Victim-assailant relationships in sexual assaults 
As seen in Table 6, women who presented at the clinic after having been sexually assaulted 
by their intimate partners were older, were of Swedish ethnicity less often, were under the 
influence of alcohol at the time of the assault less often, had a history of prior assaults more 
often, and sought help later compared to women assaulted by a stranger or an acquaintance. 
Table 6. Differences in victim characteristics between intimate partner, stranger, and acquaintance 
assaults 
 Intimate 
partner
 
Stranger
 
Acquaintance
 
p
b
 p
c
 p
d
 
 n = 102 a n=114a n = 287a    
Mean age (SD) 32.9 ±12.7 24.2 ±12.0 23.8 ±10.3 < 0.001 < 0.001 NS 
Victim’s ethnicity (% 
Swedish) 
54/102 
(53%) 
98/114 
(86%) 
234/287 
(82%) 
< 0.001 < 0.001 NS 
Victim under 
influence of alcohol 
27/94 
(29%) 
79/110 
(72%) 
204/280 
(73%) 
< 0.001 < 0.001 NS 
Previous history of 
sexual assault 
61/96 
(64%) 
34/102 
 (33%) 
113/276 
(41%) 
< 0.001 < 0.001 NS 
Time between assault and examination 
≤ 72hrs 66/102 
(65%) 
96/114 
(84%) 
223/287 
(78%) 
0.001 0.01 NS 
≥ 72hrs 36/102 
(35%) 
18/114 
 (16%) 
64/287 
 (22%) 
Pearson’s Chi-square test or Fisher’s exact test for categorical variables, ANOVA for continuous variables. 
 a Variable analyses were based on differing denominators, as determined by missing data. b P-value intimate 
partner vs. stranger, c P-value intimate partner vs. acquaintance, d P-value stranger vs. acquaintance. NS = not 
statistically significant. 
 
Further, the violence and sexual acts used in the intimate partner assaults were of a more 
severe kind, more frequently involving the use of multiple types of violence and multiple 
sexual acts (see Table 7). 
  
 38 
Table 7. Differences in assault characteristics between intimate partner, stranger, and acquaintance 
assaults 
 Intimate 
partner
 
Stranger
 
Acquaintance
 
p
b
 p
c
 p
d
 
 n = 102 a n=114a n = 287a    
Type of assault       
Vaginal 82/102 
(80%) 
61/114 
(54%) 
197/287 
(69%) 
< 0.001 0.03c 0.03c 
Anal 26/102 
(25%) 
7/114  
(6%) 
41/287 
(14%) 
< 0.001 0.01 0.02 
Oral 25/102 
(25%) 
14/114 
(12%) 
59/287 
(21%) 
0.02 NS 0.05e 
Vaginal + other 31/102 
(30%) 
15/114 
(13%) 
66/287 
(23%) 
< 0.001 NS NS 
Attempt 2/102 
(2%) 
22/114 
(19%) 
11/287 
(4%) 
< 0.001 NS < 0.001 
Others 6/102 
(6%) 
20/114 
(18%) 
28/287 
(10%) 
0.01 NS 0.03e 
Type of violence       
Any violence 91/101 
(90%) 
88/110 
(80%) 
159/287 
(55%) 
NS < 0.001 < 0.001 
Attempts of 
strangulation 
21/102 
(21%) 
9/114 
(8%) 
2/287 
(1%) 
0.01 < 0.001 < 0.001 
Kick 17/91 
(19%) 
3/88 
(3%) 
0/287 
(0%) 
0.001 (< 0.001) (0.01) 
Multiple violence 49/101 
(49%) 
32/110 
(29%) 
41/287 
(14%) 
0.004 < 0.001 0.001 
Holding 28/102 
(27%) 
52/114 
(46%) 
101/287 
(35%) 
0.04e NS 0.04e 
Pearson’s Chi-square test or Fisher’s exact test for categorical variables. a Variable analyses were based on 
differing denominators, as determined by missing data. b P-value intimate partner vs. stranger, c P-value intimate 
partner vs. acquaintance, d P-value stranger vs. acquaintance. e Not statistically significant according to the 
Bonferroni correction.  NS = not statistically significant. 
 
6.1.2 Multiple violence 
In the crude analysis, factors associated with an increased risk of being exposed to multiple 
violence were the assailant being either a stranger or an intimate partner and the victim being 
over 45 years old, not being of Swedish ethnicity, and not having been under the influence of 
alcohol during the assault. Furthermore, findings of extra-genital injuries and assaults 
consisting of multiple sexual acts were associated with an increased risk of being exposed to 
multiple violence. After adjusting for all factors in the multivariable model, only the assailant 
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being an intimate partner (OR = 4.1, 95% CI [1.9, 9.0], p < 0.001) and extra-genital injury 
(OR = 5.0, 95% CI [2.6, 9.5], p < 0.001) were associated with multiple violence. 
6.1.3 Genital injuries 
Genital injuries were only found in 20% of all women in this study. Genital injuries were 
most commonly located in the posterior fourchette (35%), in the vulva (13%), on the labia 
minora (12%) and in several locations (19%). The injuries were most often small lacerations. 
The genital injury prevalence was almost tripled in women examined within 72hours 
compared with those examined after 72 hours (23.7% vs. 8.3%, p < 0.001). In logistic 
regression, the victim-assailant relationship was not associated with genital injury. The 
adjusted analysis showed that the only association between the risk of presenting at the clinic 
with genital injuries was with being examined within 72 hours after the assault (OR = 6.4, 
95% CI [2.4, 17.4], p < 0.001).  
6.1.4 Extra-genital injuries 
Extra-genital injuries were almost three times as common as genital injuries, 58% (263/465) 
compared with 20% (90/450). Injuries to the extremities were apparent in 52% (263/503) of 
the cases, to the head in 21% (107/503) of the cases, and to the trunk in 25% (115/462) of the 
cases. Injuries to the head were reported in 34% of the intimate partner assaults and in 29% of 
the stranger assaults, to be compared with 17% in the assaults committed by acquaintances (p 
< 0.001). In the crude analysis, extra-genital injuries were more often seen when the assailant 
was an intimate partner (OR = 1.7, 95% CI [1.1, 2.8], p = 0.03) compared to an acquaintance. 
In the adjusted analysis, the only factors that remained significantly associated with extra-
genital injury were the examination being performed within 72 hours (OR = 2.5, 95% CI [1.4, 
4.5], p = 0.002) and reports of physical violence (OR = 5.5, 95% CI [3.0, 10.4], p < 0.001).  
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6.2 STUDY II 
6.2.1 PTSD and depression at six months 
Of the 63% of victims who completed the six-month follow-up, 36.8% met all 6 criteria for 
PTSD according to the SCID-I interview. The results from the interviews are presented in 
Figure 6. 
Figure 6. Results from the SCID interviews six months after sexual assaults (N = 201) 
 
After having excluded those women who did not meet a Criterion A trauma (n = 22), the 
PTSD prevalence was 41.3% (74/179), and 54% had a high symptom load of B-, C-, and D- 
symptoms. 
If one also excluded the 39 women who, according to the PDS questionnaire, already had 
pre-existing PTSD at the time of the assault, 38.6% (54/140) had developed PTSD at six 
months. 
Regardless of PTSD status, 47.5% suffered from moderate or severe depression at six months 
according to the Beck Depression Inventory (BDI). 
6.2.2 Predicting the development of PTSD in sexual assault victims 
Three regression analyses were conducted separately. These analyzed psychometric 
variables, victim characteristics, and assault characteristics. The variables in these regressions 
were all found to be significant in crude analysis.  
Of the psychometric variables entered (depression, dissociation, re-experience, avoidance, 
arousal, and ASD), severe depression (OR = 2.75, 95% CI [1.55, 4.52], p = 0.002) and ASD 
(OR = 2.61, 95% CI [1.14, 6.00], p = 0.031) at baseline were associated with the development 
of PTSD in the multivariable model. 
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Of the victim characteristics (lifetime depression, psychiatric treatment history, history of 
sexual assault in childhood, history of sexual assault in adulthood, history of  ≥ 2 traumatic 
events, and employment status), a history of  ≥ 2 traumatic events (OR = 2.02, 95% CI [1.10, 
4.15], p = 0.040) and a psychiatric treatment history (OR = 2.01, 95% CI [1.05, 3.83], p = 
0.034) were associated with the occurrence of PTSD. 
Of the assault variables (physical injury, victim-offender relationship, perceived life threat, 
type of sexual assault, whether the victim had been under the influence of alcohol, and the 
severity of physical violence during the assault), perceived life threat (OR = 2.15, 95% CI 
[1.01, 3.76], p = 0.044), having been sexually assaulted by a group (OR = 3.84, 95% CI [1.16, 
10.69], p = 0.027), having been subjected to several sexual acts (OR = 2.71, 95% CI [1.39, 
4.29], p = 0.004), and having been injured (OR = 2.07, 95% CI [1.00, 4.54], p = 0.050) were 
found to be significant risk factors. Suffering from amnesia was found to be a protective 
factor for PTSD (OR = 0.31, 95% CI [0.07, 0.95], p = 0.038) in the crude analysis; however, 
not in the adjusted analysis. The significant predictors from these three initial regressions 
were then simultaneously entered into a final model predicting PTSD (Table 8). 
 
 
 
Table 8. Factors associated with PTSD six months after sexual assault (final model, adjusted for initial 
PTSD status) 
 Univariable Multivariable 
 % with PTSD OR [95% CI] AOR [95% CI] 
Sexually assaulted by group 65.0 3.10** [1.29,8.03] 4.01* [1.18, 152] 
ASD at baseline 43.2 3.92**[1.53, 10.06] 4.96* [1.30, 18.6] 
Multiple acts during assault 48.2 2.32**[1.26, 4.29] 2.93** [1.49, 6.14] 
Physical injury 40.4 3.11**[1.43, 7.24] 2.48* [1.22, 6.50] 
Severe depression at baseline 57.1 3.36**[1.78, 6.32] 2.33* [1.03, 5.10] 
History of ≥ 2 traumatic events 50.0 2.62**[1.41, 4.85] 1.91* [1.14, 3.72] 
Psychiatric treatment history 59.6 2.45**[1.33, 4.50] 1.93 [1.00, 3.81] 
Perceived life threat 53.8 2.30**[1.23, 4.32] 1.34 [0.60, 3.89] 
Hosmer and Lemeshow Test: 0.86. OR = Odds Ratio, AOR = Adjusted Odds Ratio, CI = Confidence Interval, 
ASD = Acute Stress Disorder. *p < 0.05.  **p < 0.01. ***p < 0.001. 
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6.2.3 ASD as a predictor of PTSD 
Although ASD was found to be associated with the development of PTSD at six months in 
both the crude and adjusted analyses, the use of ASD as a predictor of PTSD had its 
limitations. Even though the majority of the women suffered from ASD at the two-week 
follow-up, only 43% of these women continued developing PTSD. Thus, ASD, as a 
predictor, had high sensitivity (67/ [67+6] = 92%), but low specificity (38/ [38+88] = 30%) 
and a low positive predictive value (67/ [67+88] = 43%); see Figure 7. 
Figure 7. ASD as a predictor of PTSD 
 
 
 
 
 
 
 
 
6.3 STUDY III 
6.3.1 Diurnal variations of stress hormones 
Using repeated-measures ANOVA, we found that all steroids, apart from the estrogens, had a 
significant within-subject variation, indicating that a circadian rhythm existed during the 
follicular phase of the menstrual cycle (Figure 8). All steroids had their peak concentration 
around 08:00 (e.g., just after awakening), apart from allopregnanolone, that had a more flat 
curve with the highest concentrations throughout the day and peak concentrations around 
12:00.  
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Figure 8. Serum concentrations of allopregnanolone, cortisol, cortisone, pregnenolone, 
17OH-pregnenolone, DHEA, testosterone, androstenedione, 17OH-progestrone, estrone, and 
estradiol during 24 hours presented as mean ± SEM. 
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6.4 STUDY IV 
6.4.1 Steroid concentrations in predicting PTSD 
In this cohort, 63% (108/171) completed the six-month follow-up, and of these, 36% had 
developed PTSD. The characteristics of the PTSD group and the non-PTSD group at six 
months are presented in Table 9. 
Table 9. Demographic data, baseline characteristics in women with PTSD compared to those without 
PTSD at six months. Continuous data presented as median (range), and categorical data presented as 
percents 
 PTSD 
N=38 
Non-PTSD 
N=69 
p-Value between 
groups 
Age, years 26.4 (18-59) 26.6 (18-44) NS 
BMI 24.6 (19-28) 23.7 (19-29) NS 
Oral contraceptive use (%) 31.6 44.9 NS 
Smoking 36.4 35.4 NS 
Days between assault and acute 
visit  
2.35 (0-16) 3.04 (0-24) NS 
BMI = Body Mass Index,  NS = not statistically significant 
Differences in steroid serum concentrations at the acute visit between women who developed 
PTSD and those who did not were analyzed using Mann-Whitney U test. As seen in Table 
10, there were no differences in serum concentrations for any of the steroids between the two 
groups.  
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Table 10. Concentrations of steroids (ng/mL) in serum at the acute visit after sexual assault (T1) in 
women with PTSD compared to those without PTSD at six months (T3). Data presented as median 
(range). 
 PTSD Non-PTSD  
 N=38 N=69 p-value* 
Allopregnanolone 0.11 (0.035-0.962) 0.12 (0.050-0.627) NS 
Cortisol 95.0 (29-292) 95.0 (34-329) NS 
Cortisone 21.00(11-31) 23.00 (4-36) NS 
11-DC 0.10 (0.99-1.40) 0.11 (0.00-1.43) NS 
Pregnenolone 1.40 (0.50-4.80) 1.50 (0.40-3.80) NS 
17OH-pregnenolone 1.29 (0.10-13.70) 1.35 (0.00-11.10) NS 
DHEA 4.60 (1.20-11.10) 5.00 (0.10-10.90) NS 
Total ∆5 steroids 7.60 (2.50-29.60) 7.90 (1.90-25.80) NS 
17OH-progesterone 0.16 (0.00-2.00) 0.12 (0.00-1.06) NS 
Ratio Cortisol/17OH-
proprogesterone  
553.14 (17-6267) 833.33 (50-7700) NS 
Androstenedione 0.76 (0.15-1.94) 0.85 (0.25-2.50) NS 
Testosterone 0.24 (0.08-1.24) 0.24 (0.07-1.34) NS 
* P-value according to Mann-Whitney U test. Total ∆5 steroids = Pregnenolone + 17OH-pregnenolone + 
DHEA. 
 
The term “∆5 steroids” was used for pregnenolone, 17OH-pregnenolone, and DHEA. These 
steroids all have a double bond between carbons 5 and 6 and are synthesized along the delta-5 
pathway (see Section 2.3.1).  
6.4.1.1 Bivariate correlations 
As seen in Table 11, none of the steroids were correlated with PTSD symptoms at either the 
two-week or six-month follow-up. Low concentrations of all of the ∆5 steroids were 
associated with greater depression symptoms at six months, and 17OH-pregnenolone was 
also associated with depression symptoms after two weeks. 
Concentrations of cortisol and the ∆5 steroids were negatively correlated with a prior assault 
history, and the concentrations of allopregnanolone and the ∆5 steroids were negatively 
correlated with a psychiatric treatment history. PTSD and depression were positively 
correlated with each other at both time points; however, PTSD at two weeks was not 
correlated with PTSD at six months. None of the correlations or the absence of a correlation 
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changed when performing a subgroup analysis of patients who sought help within 24 or 72 
hours. 
 
6.4.1.2 Logistic regression 
When using binary logistic regression none of the steroids were associated with the 
development of PTSD at six months. This result remained after adjusting for the number of 
days that had elapsed since the assault and the menstrual cycle phase. Low levels of the 
steroids in the ∆5 steroid group were associated with the development of depression at six 
months (OR = 3.9, 95% CI [1.08, 8.26], p = 0.035). However, this association did not remain 
after adjusting for trauma history, psychiatric treatment history, and menstrual cycle phase. 
Low concentrations of cortisol were associated with a history of earlier traumatization (OR = 
2.5, 95% CI [1.01, 6.7], p = 0.048), an association that remained after adjusting for the 
number of days that had elapsed since the assault. The association between low levels of 
steroids in the ∆5 steroid group and earlier traumatization did not remain after adjusting for 
menstrual cycle phase. Low concentrations of allopregnanolone were associated with a 
psychiatric treatment history (OR = 6.0, 95% CI [1.7-21.8], p = 0.007), an association that 
remained after adjusting for earlier traumatization, oral contraceptives, and the number of 
days that had elapsed since the trauma. 
  
Table 11. Correlations between serum steroid concentrations, oral contraceptives, smoking, PTSD, depression, prior trauma 
history, and psychiatric treatment history. 
 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 
1.Allopregnanolone -.25* -.08 .05 .58** .30** .42** .31** .40** -.50** -.02 .12 .03 -.00 -.07 -.07 -.29** 
2. Cortisol 1 .71*** 0.55** -.04 .58*** .39*** .45*** .30** .13 -.01 -.15 -.01 -.03 .03 -.26* -.16 
3. Cortisone  1 0.60** .17 .59*** .42*** .51*** .18 -.15 .06 .09 -.19 .08 .17 -.12 -.32** 
4.11-DC   1 .44** .35** .53** .44** .59** -.07 .15 -.15 .05 -.07 -.02 -.18 -.15 
5.17OH-prog.    1 .33** .54*** .25* .35*** -.39** .15 .01 .08 -.05 -.01 -.01 -.20* 
6. 17OH-preg.     1 .76*** .87*** .69*** -.15 .08 .03 -.21* -.02 -.22* -.24* -.29** 
7. Pregnenolone      1 .71*** .73*** -.24* .05 .05 -.21 -.11 -.25* -.17* -.27** 
8. DHEA       1 .75*** -.12 .09 .11 -.19 .00 -.21* -.21* -.23* 
9. Total ∆5 steroids        1 -.20* .07 .06 -.21 -.06 -.25* -.21* -.29* 
10. OC         1 .06 -.08 -.06 -.12 -.15 -.02 .07 
11. Smoking          1 -.13 -.07 .01 -.06 .03 -.20* 
12. PTSD T2           1 .19* .11 .14 .31*** .20* 
13. Depression T2            1 .27** .57*** ,34** -.00 
14. PTSD T3             1 .60*** .28** .17* 
15. Depression T3              1 .34*** .28** 
16. PAH               1 .20* 
17. PTH                1 
OC = Oral Contraceptives, PAH = Prior Assault History, PTH = Psychiatric Treatment History. T1 = acute visit, T2 = 10-14 days follow-up visit, T3 = six-month visit. * P 
<.05, ** p < .01, *** p < .001. 
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6.5 STUDY V 
In order to examine the sensitivity of the GABA-A receptor in patients with PTSD, a total of 
12 patients and 16 controls completed a total of 57 challenges. Ten patients and 10 controls 
were meant to be included in each challenge. However, in the diazepam and flumazenil 
challenge 9 patients but 10 controls were included. In the allopregnanolone challenge, 10 
participants were included in each group, but one control was excluded because of technical 
problems during the challenge. 
Baseline characteristics between the PTSD patients and the non-traumatized controls without 
PTSD are presented in Table 12. 
Table 12. Demographic data, baseline characteristics, and subjective scoring of anxiety in women 
with PTSD and controls. Data presented as median (range) and mean ± SEM 
 PTSD 
N=12 
Controls 
N=16 
p-Value between 
groups 
Age, years 24.8 (18-37) 27.7 (20-39) NS 
BMI 24.6 (19-28) 22.6 (19-29) NS 
Cycle day 10.3 (6-12) 8.9 (5-12) NS 
S-allopregnanolone, nmol/L 0.51 ± 0.06 0.54  ± 0.42 NS  
SEV, degrees/sec 490 ± 13.4 490 ± 12.8 NS 
Sedation, VAS, mm 3.3 ± 0.6 2.3 ± 0.3 NS 
SASRQ 108 (80-142) 2.7 (0-14) < 0.001 
BDI 25.9 (5-53) 1.0 (0-6) < 0.001 
STAI 49.0 (32-64) 26.8 (20-32) < 0.001 
PSS 15.0 (5-33) 1.1 (0-4) < 0.001 
SADS 1.8 (0-3) 0.1 (0-1) < 0.001 
BMI = Body Mass Index, SEV = Saccadic Eye Velocity, VAS = Visual Analog Scale 10 mm, SASRQ = 
Stanford Acute Stress Reaction Questionnaire, BDI = Beck Depression Inventory, STAI = State-Trait Anxiety 
Inventory, PSS = Panic Symptoms Scale, SADS = State Anxiety and Discomfort Scale.  
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6.5.1 Sedation 
Figure 9. Subjective ratings of sedation (delta values from baseline) after injections of 
allopregnanolone, diazepam, and flumazenil in women with PTSD compared to healthy controls. The 
injections are indicated by the vertical lines. The bracket in the diazepam graph indicates the 
significance of the difference between patients and controls. 
After an injection of 
allopregnanolone, controls 
showed an increase in 
sedation (p = 0.011). The 
PTSD patients showed a 
tendency towards increased 
sedation, though it was not 
significant. There was no 
significant difference 
between the groups (see 
Figure 9, Allopregnanolone). 
After an injection of 
diazepam, both groups 
showed a significant increase 
in sedation. However, there 
was a difference between the 
groups in that the patients 
showed less of an effect 
compared to controls  (p = 
0.027) (see Figure 9, 
Diazepam).  
After an injection of 
flumazenil, the patients 
showed an increase in 
sedation (p = 0.010), while 
the controls did not show any 
effect. However, there was 
no significant difference 
between the two groups 
regarding sedation (see 
Figure 9, Flumazenil). 
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6.5.2 Saccadic Eye Velocity (SEV) 
Figure 10. Saccadic eye velocity (delta values from baseline) after injections of allopregnanolone, 
diazepam, and flumazenil in women with PTSD compared to healthy controls. The injections are 
indicated by vertical lines. Also, a indicates the significance of the difference between the two groups 
at different time points. 
 
After an injection of 
allopregnanolone, both groups 
showed a decrease in SEV. Except 
for the first 5 minutes after 
injection, there was a difference 
between the two groups in terms of 
response (see a Figure 10, 
Allopregnanolone). Patients 
responded to a lesser degree than 
controls (a = p = 0.047). If one 
considers the response 18 minutes 
after the injection, the difference 
was even greater (a = p = 0.038). 
After an injection of diazepam both 
patients and controls responded 
with a significant decrease in SEV 
(Figure 10, Diazepam). However, 
there was no significant difference 
in reaction between the two groups.  
 
 
After an injection of flumazenil, 
there was a decrease in SEV in 
both groups (Figure 10, 
Flumazenil). This reaction was 
similar to what was seen after an 
injection of diazepam. There was 
no significant difference in the 
reactions between the two groups.  
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7 DISCUSSION 
7.1 GENERAL DISCUSSUION 
7.1.1 Victim-assailant relationship in sexual assaults 
The major findings of Study I confirmed the hypothesis that sexual assaults committed by an 
intimate partner differ from other victim-assailant assaults regarding the use of violence and 
coercion. Victims of intimate partners were exposed to more severe violence, including hits, 
kicks, and attempts of strangulation, while violence used in stranger and acquaintance 
assaults more often consisted of simply holding the victim down during the assault. 
Subsequently, women who were sexually assaulted by their intimate partners also showed a 
trend towards presenting with more extra-genital injuries. Genital injury prevalence, however, 
was not associated with the victim’s relationship with the assailant. 
These results are interesting because they differ somewhat from the majority of the 
international literature. Most of the earlier studies have reported stranger assaults as being 
more violent and more associated with injuries compared to assaults by a known assailant 
[48,151,152]. However, our results are in line with those studies that have separated intimate 
partner assaults from other known-assailant assaults [50,51,153]. When doing so, intimate 
partner assaults have been suggested to be more violent. There are, however, still some 
discrepancies between the studies. Murphy and colleagues [51], for example, found that 
genital injury prevalence was higher in intimate partner assaults but that extra-genital injuries 
were more common among stranger assaults. These discrepancies may be caused by the use 
of different methodologies but one could also speculate as to whether stranger assaults in 
Sweden are less violent compared to those in the US or whether Swedish women are more 
likely to report sexual violence than women from other western countries. The latter 
interpretation is at least partially supported by the fact that in crime statistics, a larger 
proportion of sexual assaults are reported in Sweden compared to in the US and the UK 
[12,154].  
Despite the discrepancies described above, our study supports the knowledge that sexual 
assaults within a relationship most often co-occur with physical and psychological violence; 
these assaults are a form of intimate partner violence (IPV) that can be called intimate partner 
sexual violence (IPSV). A recently published review concluded that the average prevalence 
of IPSV within IPV survivors was about 36% [155]. Women who were sexually assaulted by 
their partners more often had a history of earlier assaults, suggesting repetitive assaults within 
the relationship. Also, women who were sexually assaulted by a partner had a high risk of 
being sexually assaulted in another relationship [156]. In our study, we found that women 
who were sexually assaulted by a partner presented at the clinic later than women who were 
assaulted by an acquaintances or a stranger. The reason for this is unknown, but it could be 
caused by increased self-blame, as well as lack of support in reporting and a desire to 
maintain a “whole” family. It is also well-known that along the same line as the results for 
late disclosure and presentation at the clinic, IPSV prevalence rates are underestimated 
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because women in relationships are hesitant to accept that the violence they have been 
exposed to is, in fact, a rape or a sexual assault. 
Finally, women in intimate partner assaults were older, less often of Swedish origin, and less 
often under the influence of alcohol during the time of the assault compared to the other 
groups. This can be explained by the fact that in contrast to the two other assailant groups, in 
which an assault most often occurs during or after social interactions where alcohol is being 
served, intimate partner assaults occur within the home of the victim. It is also more common 
among older women to be in a steady relationship, and in a relationship, alcohol is not needed 
to attract or mislead the victim. The over-representation of women born outside Sweden in 
the group of women assaulted by their partners may be explained by socioeconomical and 
cultural factors, but it has to be backed up with further studies.  
7.1.2 Predicting PTSD in sexual assault victims 
After having excluded those women who had not met a criterion A trauma and those who 
were assessed as having pre-existing PTSD at the time of the assault, 39% of the women in 
Study II had developed PTSD six months after the sexual assault. Even though the percentage 
of women who dropped out between the two-week and six-month assessments was almost 
37%, the PTSD prevalence was comparable to earlier longitudinal and larger cross-sectional 
studies. One can assume that the PTSD prevalence would have been even higher if less 
attrition had been seen (see Section 7.2.2.1 on selection bias).  
The rationale for Study II was to see whether it was possible to identify those women who 
had the highest risk of developing PTSD within a group of acute-medical help-seeking 
women after rape. We therefore focused on risk factors for PTSD that could be identified at 
the acute visit and/or at a two-week follow-up visit. It has been suggested that post-assault 
psychosocial factors have more influence on the development of PTSD than pre-existing 
variables or the circumstances around the current assault [68]. However, the post-assaults 
variables cannot as easily be identified at the acute visit and cannot be used as immediate 
predictors to identify those women at greatest risk. In the present study, the highest risk of 
developing PTSD was seen in women who had been sexually assaulted by multiple 
assailants, were suffering from ASD shortly after the assault, had been subjected to several 
acts during the assault, had been injured, had severe depression at the two-week follow-up,  
and had a history of ≥ 2 traumatic events.  
The finding that women sexually assaulted by a group (i.e., more than one assailant) had the 
highest risk of developing PTSD probably indicates the extremely threatening nature of these 
assaults. In the same way, the association between having been exposed to several sexual acts 
during the assault and PTSD probably indicates more severe interpersonal violence. 
Surprisingly, single-stranger assaults were not associated with an increased risk of developing 
PTSD as compared to the other assailant groups in this cohort. This is contrary to two earlier 
studies in which the victims of strangers were found to have more PTSD symptoms than 
victims of intimate partners and acquaintances [73,74]. However, in reading these studies, it 
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is unclear whether they have discriminated between single- and multiple-stranger assaults. If 
this is not the case, the association between stranger assaults and PTSD may have become 
smaller. In the present study, even though the results are not significant, women assaulted by 
an intimate partner had the highest risk of developing PTSD as compared to the other single-
assailant groups. This supports the finding from Study I that sexual assaults within 
relationships are the most violent.  
Unlike study populations in large cross-sectional studies from national representative 
samples, the women in this study represented an already-heavily-traumatized group. The 
majority of the women had a history of earlier sexual assaults in both childhood and 
adulthood. We saw an almost linear effect between the number of traumatic experiences and 
the risk of developing PTSD. Because of the high degree of traumatization in this sample, a 
history of a single earlier trauma or sexual assault did not increase the risk of PTSD. 
However, a variable defined as having experienced two or more traumatic events (≥ 2 
traumas) remained a significant risk factor in the final multivariable model. The findings 
regarding childhood sexual assault were in line with earlier studies; it was not found to be a 
significant predictor of PTSD on its own. However, the link between childhood sexual assault 
and PTSD seems to be mediated through the increased risk of being victimized in adulthood, 
which subsequently increases the risk of developing PTSD [18,69] .   
Consistent with the earlier literature [157], we found that women who had been depressed in 
the past and had severe depression in the immediate aftermath of the rape were at an 
increased risk of presenting with PTSD at the six-month assessment. Even though this finding 
could be partially due to the overlapping symptoms of these disorders (e.g., concentration and 
sleep disturbances), it is also very likely that the impact of the assault is intensified for 
previously depressed patients and that the trauma causes a new episode of depression.  
Finally, the association between ASD and PTSD is worth mentioning. ASD was associated 
with the development of PTSD in the final multivariable model. However, the ceiling effect 
limits ASD´s ability to predict PTSD. That is, even though a vast majority of the women had 
ASD at the two-week assessment, far from all of them continued to develop PTSD. 
7.1.3 Diurnal variations of endogenous steroids 
In Study III six classes of steroids were measured and analyzed regarding possible diurnal 
variations: the anesthetic steroid allopregnanolone, glucocorticoids (cortisol, cortisone, 11-
deoxycortisol), androgens (androstenedione, testosterone, DHEA), pregnenes (pregnenolone, 
17OH-pregnenolone), progestins (progesterone, 17OH-progesterone), and estrogens (estrone, 
estradiol). We found that all the measured steroids, apart from the estrogens, had a 
significant diurnal variation in premenopausal women in the follicular phase of the menstrual 
cycle. This has partly been described in the literature; however, the finding of a diurnal 
variation in allopregnanolone was surprising as this has not been described before and no 
such variation had been seen in the luteal phase of the menstrual cycle [117]. Because 
allopregnanolone is synthesized from progesterone, allopregnanolone concentrations are 
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known to be high during the luteal phase of the menstrual cycle [158] and therefore may 
blunt the nocturnal rhythm in the adrenals. Further, we found that the androgens, the 
pregnenes, and the progestins all had similar diurnal variation curves as the glucocorticoids 
(i.e., with a peak in the morning just after awakening and the lowest concentrations during the 
night). Allopregnanolone had a somewhat similar curve; however; it was more flat with a 
peak concentration around 12.00. The reason for this delay and the different steepness of the 
curve may be caused by the longer biosynthesis pathway to allopregnanolone; however, this 
must be explored in further studies. 
Thus, these results suggested that when analyzing the serum concentrations of the steroids in 
Study IV, we had to adjust for their diurnal variation.  
7.1.4 Concentrations of endogenous steroids in predicting PTSD  
The major findings of Study IV were that low concentrations of cortisol and all of the ∆5 
steroids (pregnenolone, 17OH-pregnenolone, and DHEA) shortly after rape were associated 
with a history of earlier traumatization and that low allopregnanolone concentrations shortly 
after rape were associated with a psychiatric treatment history. However, there was no 
association between any of the steroids and pre-existing PTSD or the development of PTSD 
at six months. The ∆5 steroids were negatively correlated with depression at six months; 
however, not in the adjusted analysis. 
The finding that cortisol concentration measured in the aftermath of rape was not associated 
with the development of PTSD is contrary to what has been found in patients after motor 
vehicle accidents [92,93,94,95], where low cortisol concentrations were found to be 
associated with the development of PTSD. The results are, however, concordant with earlier 
studies of sexually assaulted women, in which low cortisol concentrations on their own were 
not associated with the development of PTSD [96,97]. Instead, lower concentrations of 
cortisol were seen in women with a prior trauma history, who subsequently had an increased 
risk of developing PTSD. Similarly, we found that allopregnanolone concentrations were 
negatively correlated with a psychiatric treatment history (i.e., women who reported a history 
of psychiatric illness presented with reduced allopregnanolone concentrations in the 
aftermath of rape). A psychiatric treatment history and a prior trauma history were found to 
be risk factors for the development of PTSD after rape in Study II, and this association was 
also seen in this study.  
Another interesting observation in this study was the possible interaction between 
allopregnanolone and cortisol and perhaps the subsequent interaction between the menstrual 
cycle and the HPA axis. We saw a small but significant negative correlation between 
allopregnanolone and cortisol (r = -,25, p < .01) (i.e., cortisol concentrations were lower when 
allopregnanolone concentrations were high). This finding is in line with findings in rodents, 
where low allopregnanolone concentrations were found to potentiate cortisol responses and 
vice versa [159]. In a study of patients with premenstrual dysphoric disorder (PMDD) [117], 
the patients and the healthy controls had comparable concentrations of cortisol. However, 
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patients with higher concentrations of allopregnanolone displayed blunted nocturnal cortisol 
levels. The researchers therefore suggested that the diurnal secretion of cortisol in the luteal 
phase could be influenced by allopregnanolone concentration. Further, they suggested that the 
timing of the blood sampling, as well as individual levels of allopregnanolone, could explain 
the discrepancies in studies examining the HPA axis in PMDD patients. We therefore assume 
that when interpreting the HPA axis in PTSD patients, allopregnanolone concentrations must 
be taken into account. Not making adjustments for female patients being in the luteal phase of 
the menstrual cycle (i.e., when allopregnanolone concentrations are known to be high) 
[158,160] could potentially blunt the results. Also, in a recent study, Inslicht and colleagues 
[161] discussed the difficulties involved in interpreting neurosteroid responses in 
premenopausal women, suggesting that the reproductive hormones may be involved in the 
modulation of the HPA axis. In the present study, we also saw a highly positive correlation 
between allopregnanolone and the ∆5 steroids (pregnenolone, 17OH-pregnenolone, DHEA). 
The ∆5 steroids are mainly synthesized in the adrenal cortex but to some extent, also in the 
ovary [162]. Because the correlations were based on z-scores (i.e., after each sample had been 
adjusted for the diurnal variation), the correlations cannot solely be caused by similar diurnal 
variations. Instead, we assumed that this correlation was associated with the phases of the 
menstrual cycle. Higher concentrations of at least pregnenolone and 17OH-progesterone in 
the luteal phase compared to the follicular phase have been shown before [158].  When we, in 
the present study performed subgroup analyses excluding those patients who, according to 
their progesterone levels, were in the luteal phase, the negative association between the ∆5 
steroids and the development of depression was erased. The association between low levels 
of ∆5 steroids and depression was also erased after adjusting for earlier trauma and a 
psychiatric treatment history.  
The present study is unique because it is the first study to explore the relationship between the 
concentrations of steroids, intermediates and final products in the steroid biosynthesis 
pathway in the immediate aftermath of a trauma and the development of PTSD and 
depression. In this study samples were analyzed mainly using high-specificity validated LC-
MS/MS methods, technique considered to be the “gold standard” for the analysis of 
endogenous steroids [163]. However, it is possible that the use of other techniques to measure 
the HPA axis would have provided more information. As a single blood or urine sample only 
provides a small “snapshot”, 24-hour sampling or low-dose dexamethasone tests might have 
given a more complete picture of the HPA axis function. Still, our interpretation of these 
results is that even though steroid concentrations in the aftermath of rape could not predict the 
development of PTSD in this study, the low steroid concentrations in women with earlier 
trauma and a psychiatric treatment history represent an increased vulnerability in the victim 
and probably an impairment of the HPA axis due to repetitive stress. 
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7.1.5 GABA-A receptor function in PTSD 
The major findings in Study V were that the PTSD patients were less sensitive to 
allopregnanolone compared with healthy controls. This was seen in the form of a difference 
in SEV between the groups after injection. The PTSD patients were also less sensitive to 
diazepam compared to the controls, with a significantly lower increase in sedation. Further, 
the PTSD patients responded with an increase in sedation after injections of flumazenil, while 
this was not seen in the controls. 
Our hypothesis that PTSD patients would have an increased sensitivity to allopregnanolone in 
the same way as burn-out patients [135] was not confirmed. Hence, an up-regulation of the 
α4, β, δ subunit, as had been suggested, is unlikely. Instead, our results indicating decreased 
sensitivity in the receptor is more in line with the findings for patients with panic disorder 
[136] and PMDD [160]. In these studies, the decreased sensitivity was explained by an 
acquired tolerance, probably due to a down-regulation of the GABA-A receptor. As 
allopregnanolone concentrations are known to be high during stress [164], the trauma and 
constant re-experiencing seen in PTSD patients (probably leading to repetitive periods with 
high allopregnanolone concentrations) could theoretically have caused an acquired chronic 
allopregnanolone tolerance [165]. 
The reduced sensitivity to diazepam in patients with PTSD was not confirmed via differences 
in SEV between the groups but through differences in sedation.  The regulation of sedation 
has been suggested to be dependent on the α1, γ subunit [166], leading us to assume that 
PTSD patients also have tolerance in this system. Such tolerance could, of course, also have 
been caused by the patient having repeated alcohol or benzodiazepine intake; however, all 
forms of substance abuse were part of the study’s exclusion criteria. 
Finally, we found that in line with our hypothesis, the PTSD patients experienced an 
agonistic effect when given flumazenil. The patients reacted with increased sedation, while 
this was not seen in the controls. However, we made the surprising discovery that the controls 
also experienced an agonistic effect when given flumazenil regarding SEV. Both patients and 
controls reacted with a decrease in SEV after flumazenil injection. To our knowledge, this 
has not been described earlier, and in the study of burn-out patients [135], this effect was not 
seen in the controls. 
To our knowledge, this is the first time that the GABA-A receptor has been examined in 
PTSD patients using an objective and reliable measure such as SEV. Even though subjective 
ratings of sedation are not as objective as SEV, the results in sum suggest that PTSD patients 
have an altered sensitivity to GABA-A-receptor-active substances. Subsequently, 
benzodiazepines and other GABA-A-receptor-active substances will be less effective in 
patients with PTSD. We know that benzodiazepines are still being widely used in patients 
with PTSD [114] and that some even claim that the use of benzodiazepines can increase 
PTSD prevalence after trauma [167]. The results from the present study therefore provide 
further proof of the impropriety of the use of benzodiazepines in this group of patients. 
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7.2 METHODOLOGICAL CONSIDERATIONS  
7.2.1 Random errors 
Research errors can be classified as random or systematic [168]. Random error stands for 
variability in the data that we cannot explain and that affects the precision of the estimates 
presented by the width of the confidence interval. Variation may reflect hidden biases that 
may not have been measured and perhaps not even discovered. The confidence intervals 
indicate the amount of random error in the estimate, and the random error will decrease as the 
size of the study population increases. 
Study I represents a fairly large sample of consecutive women seeking help at the 
Emergency Clinic for Raped Women. However, when we performed sub-group analyses of 
different perpetrator groups, the confidence intervals increased and the study would have 
benefited from a larger sample.  
Studies II and IV represent a cohort of sexually assaulted women recruited at the two- week 
follow-up after sexual assault. Even though the confidence intervals indicate that a higher 
validity would have been established with a larger sample, the majority of errors (as in all 
cohorts) are probably mainly caused by systematic errors. 
In Study III, only 10 women were examined regarding the diurnal variation of various 
endogenous steroids. However, the results were clear, and probably would not have been 
drastically affected by a larger sample.  
In Study V, the use of 10 individuals in each group at each challenge was based on earlier 
studies in which similar sample sizes have been able to provide sufficient results 
[135,138,139].  However, as we saw that the results had a large amount of variability within 
the groups as well, a larger study population might have made results more clear, if not 
changed them.  
7.2.2  Systematic errors 
Systematic errors (or biases) distort the estimates in a given direction and are generally a 
greater threat than random errors in epidemiological studies. Unlike random errors they are 
not reduced by increasing sample size. The systematic errors can be caused by the way 
subjects have been selected (selection bias), the way the study variables are measured 
(information bias) and by confusion or mixing of effects (confounders) [168]. 
7.2.2.1 Selection bias 
Study I included all consecutive patients who sought medical help during a 13-month period. 
In Stockholm, all emergency sexual assault victim care is centralized to the Emergency Clinic 
for Raped Women, and the center takes care of women from both urban and suburban areas. 
Women belong to a wide variety of ethnic and age groups, something that reduces selection 
bias. However, the results are, of course, still biased by not having any information about the 
women who did not seek any help, something that also caused selection bias in Study II and 
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IV. We know that the number of rapes reported to the police in the area are far greater than 
the number of women who seek medical help and that the number of rapes reported to the 
police probably is just a small portion of the actual number of women who were sexually 
assaulted during the same timeframe [8]. 
Selection bias in Studies II and IV was also caused by the low participation rates, 30% 
(317/1047) and 31% (171/547), respectively. This was not unexpected, because a prospective 
design involves approaching survivors in the acute aftermath of the assault; it is only natural 
that many will not be willing to share details about the experience. In a recent review of 
longitudinal studies on sexual assault survivors, participation rates were similar, ranging from 
12% to 69% but mostly being less than 45% [169].  
The high level of attrition between the acute visit and the six-month follow-up in Studies II 
and IV, could of course, also have caused selection bias. However, in these two studies, the 
proportion of completers by victim-assailant relationship was the same as in Study I, 
suggesting that the samples were at least representative of help-seeking women in the 
Stockholm area. However, in our attrition analysis we saw that non-completers more often 
had an alcohol abuse, were depressed, and had more avoidance symptoms at baseline than the 
completers. Both alcohol abuse and depression are known to have a high co-morbidity with 
PTSD [170,171,172] and if we are to draw any assumptions from this, it would be that PTSD 
prevalence could have been even higher at six months if attrition was lower.  
7.2.2.2 Information bias 
Information bias refers to the accuracy of the collected data, and it can also be described as 
the misclassification of discrete variables. If a variable is measured on a categorical scale, this 
misclassification leads to a person being placed in an incorrect category. 
In Studies I, II, and IV, the majority of baseline data was based on self-reports documented 
in the clinics’ structured data files. Data collection was therefore dependent on the woman’s 
report, and it is not clear how reliable it is to collect data within the context of a forensic 
examination shortly after a sexual assault. The women may still have been influenced by 
alcohol, been extremely upset, or suffered from peritraumatic dissociation. Missing data in 
the patient files and protocols from the forensic examinations were coded as “no”. Although 
no more than 17% of responses were missing for any one variable, it is possible that these 
missing data could have impacted the study findings. 
The psychometric self-assessed questionnaires used at the two-week and six-month follow-
ups in Studies II and IV and during inclusion in Studies III and V may also have caused 
information bias. A self-assessed questionnaire can be incomplete, false, or exaggerated. If no 
more than 15% of the answers in an individual’s questionnaire were missing, we imputed a 
number that was the mean of all the answers in the rest of the questionnaire. If more than 
15% of the answers were missing in a questionnaire, these answers were kept as missing 
values. The diagnosis of pre-existing PTSD at baseline was based on the answers to the PDS 
questionnaire; a questionnaire not looked upon as the gold standard when assessing PTSD 
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diagnosis. Even though the questionnaire has been used with sexual assault victims in earlier 
studies and the women had the chance to ask about the interpretation of the questions during 
the session, the diagnosis of pre-existing PTSD may have to be treated with caution.  
The occurrence or absence of PTSD at six months in Studies II and IV and during inclusion 
in Studies III and V was established using a structured clinical interview (SCID-I). Even 
though the use of interviews has been proven to be more accurate in assessing a psychiatric 
disease, it can still be biased by both the interviewer’s own interpretation of the answers and 
the victim’s ability to answer correctly. A patient may exaggerate her symptoms in order to 
get secondary disease gain and a healthy control may be willing to marginalize a symptom in 
order to fulfill inclusion criteria. The use of parallel psychometrics (i.e., both self-rating 
questionnaires and clinical interview) to assess PTSD symptoms, however, strengthens the 
studies. 
One of the most common information biases is recall bias. This occurs in studies in which 
subjects are being interviewed to obtain exposure information and identify risk factors after 
the disease (or traumatic experience) has happened. Unlike many of the large cross-sectional 
studies performed in order to identify the occurrence of PTSD and risk factors for PTSD, a 
prospective design, as in Studies II and IV, allows data collection shortly after the event, thus 
reducing the risk of recall bias.  
7.2.2.3 Confounding and intermediary factors 
The purpose of the multivariable models used in Studies I, II, and IV was to better 
understand the variables associated with the presence of injuries, reports of violence, and the 
development of PTSD and depression. As the majority of the information was taken from the 
clinic’s patient files, the number of variables was limited. For example, apart from 
information on current employment status and marital status, there was limited information 
on socio-economic status among the women. It is possible that more information on 
educational level and income would have affected the results. Variables can be confounders 
and/or intermediary variables in the causal link between a variable and a disease [173]. For 
instance, having been on sick leave for more than three months was associated with both 
alcohol abuse and PTSD. Occupational status would be a confounder if a woman who had 
PTSD used alcohol because she was unemployed. Conversely, occupational status would be 
an intermediary factor if a woman on sick leave used alcohol as a result of PTSD.  Because it 
is commonly accepted that low socioeconomic status increases the risk of both alcohol abuse 
and PTSD, it can be considered as a confounder. On the other hand, PTSD has also been 
shown to negatively affect one’s ability to sustain employment. Accordingly, socioeconomic 
status could also be an intermediary variable. The correction of intermediary factors in 
multivariable analyses can result in over-adjustment. Furthermore, including more 
independent variables would increase the risk of raising the number of women who would be 
excluded from the analysis due to missing data. 
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In Study III, confounding factors were prevented by restricting the study population, and in 
Study V, this was done by matching patients with controls. 
7.2.2.4 External validity 
Study I is based on women in all age groups (range 11 to 95) from both urban and suburban 
areas. However, the results may not be valid for women in more rural settings. The 
descriptive design also limits the chance to draw conclusions and identify causal 
relationships. 
In Studies II and IV, the inclusion criteria were being over the age of 18. Therefore, causal 
relationship between variables and PTSD cannot be drawn for younger age groups. Further, 
women were excluded if they were not literate in Swedish, thus excluding many help-seeking 
immigrants, making generalizations to other nationalities and minority groups difficult. 
In Study V, the sensitivity of the GABA-A receptor was explored in premenopausal women 
with PTSD during the follicular phase of the menstrual cycle. It is uncertain whether these 
results can be reproduced in the luteal phase of the menstrual cycle, in older age groups, and 
in male subjects with PTSD. 
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8 CONCLUSIONS AND CLINICAL IMPLICATIONS 
 
 Sexual assaults committed by intimate partners involve more physical violence and 
result in injuries just as often as assaults committed by strangers. Thus, intimate 
partner assaults should be taken just as seriously as those committed by strangers and 
improved victim services and prevention stategies should be built on this knowledge. 
 
 Development of PTSD is common in the aftermath of sexual assaults and in this 
cohort almost 40% had developed PTSD at the six-month follow-up.  
This finding supports the importance of sexual assault centers not only providing 
medical help and forensic examinations, but also psychological help and follow-up.  
 
 An increased risk of developing PTSD is caused by a combination of victim 
vulnerability (prior trauma history and co-morbid depression) and the extent of the 
dramatic nature of the current assault (group assault, multiple acts during the assault, 
and having been injured). Because of the high ceiling effect, ASD on its own was 
found being a poor predictor of PTSD development. With this knowledge women at 
greatest risk of developing PTSD can be identified and therapeutic resources can be 
directed. 
 
 All the endogenous steroids we measured, apart from the estrogens, had a significant 
diurnal variation in the follicular phase of the menstrual cycle. The pregnenes, 
progestins, and androgens had a similar diurnal variation curve as cortisol (with peak 
concentrations just after awakening), apart from allopregnanolone, which had a less 
steep curve and high concentrations throughout the day. These results suggest that 
when interpreting concentrations of these steroids their diurnal variation have to be 
adjusted for.  
 
 None of the steroids were associated with the development of PTSD. However, low 
concentrations of cortisol, pregnenolone, 17OH-pregnenolone, and DHEA were 
found in patients with a prior trauma history, and low concentrations of 
allopregnanolone were seen in patients with a psychiatric treatment history. As both 
prior trauma history and psychiatric treatment history have been found to be risk 
factors for PTSD, our findings suggest an increased vulnerability in these patients and 
probably an impairment of the HPA axis due to repetitive stress. 
 
 Patients with PTSD have a reduced sensitivity to GABA-A-receptor-active 
substances. As a consequence of this, benzodiazepines and other GABA-A-receptor-
active compounds, such as sleeping pills, will be less useful for this patient group. 
  
 62 
 
 63 
9 IMPLICATIONS FOR FUTURE RESEARCH 
During the work on this thesis, some ideas for future research emerged.  
Since we found an over-representation of immigrant women in the group of women who 
were sexually assaulted by their intimate partners, further research on sexual assaults in 
intimate partner relationships within minority groups is needed. More information about the 
prevalence of these assaults, as well as the circumstances surrounding and attitudes regarding 
disclosure, would be helpful for staff working in immigrant-dense areas, both in healthcare 
and social services.   
As we found the prevalence of genital injuries to be fairly low, meanwhile injuries are still 
being given much attention in court, a study on injuries after consensual, compared to non-
consensual, intercourse would be interesting. Results from a recently published Danish study 
[40] examining 39 cases and 98 controls suggested that differences between consensual and 
non-consensual intercourse could be identified. However, this must be backed up with larger 
studies. Preferably, this could be done in a large Nordic multi-center study. 
As Study II suggests that it is possible to identify those women at a high risk of developing 
PTSD, even in this sample of heavily traumatized women, a study of early interventions 
focusing on those women is warranted. As follow-up of this patient group often suffers from 
high drop-out rates, interventions should be easily accessible. Suggestions for early 
interventions could include mindfulness or emotional freedom technique (EFT). These are 
both techniques that can be performed at home and can be aided via the Internet.  
Another early intervention would be a form of “vaccination” against PTSD. Promising results 
regarding the prevention of PTSD have been shown in studies when subjects have been given 
high doses of cortisol immediately after a trauma. In a recently published Cochrane review 
[174] based on four RCTs [175,176,177,178], the authors concluded that there is moderate-
quality evidence for the efficacy of hydrocortisone in preventing the onset of PTSD and that 
between 7 and 13 patients would need to be treated in order to prevent the onset of PTSD in 
one patient. These studies, however, were few, small, and had multiple limitations. Further, 
none of the studies were performed on sexual assault victims, a group of patients known to be 
at the highest risk of developing PTSD.   
Finally, it would be interesting to explore associations between menstrual cycle phase at the 
time of the assault, the HPA axis response, and the development of PTSD. Studies have 
shown that women exposed to traumatic experiences during the luteal phase of the menstrual 
cycle develop more traumatic memories [179] and that women who watched emotional films 
during the luteal phase had more spontaneous intrusive recollections [180]. This was 
suggested to be caused by the higher levels of progesterone and glucocorticoids during the 
luteal phase, causing increased memory consolidation. This is, at least in part, contrary to the 
theory previously described, stating that low cortisol concentrations cause an increased risk of 
developing PTSD. However, none of the studies examining the role of menstrual cycle phase 
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explored the development of PTSD. The interaction between menstrual cycle phase and the 
HPA axis is still not fully understood [181] and must be further explored. Study IV suggests 
that cortisol concentrations are lower when allopregnanolone (as well as progestrerone) 
concentrations are high, which would be a logical way to describe an eventually increased 
risk of PTSD development after having been traumatized in the luteal phase. This is also in 
accordance with findings in rodents during pregnancy (another condition when 
allopregnanolone levels are known to be high), when the HPA axis response to stress was 
suppressed [182].  
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10 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Varje år utsätts 3-4% av den kvinnliga svenska befolkningen för ett sexuellt övergrepp. Bara 
några få procent av dessa kvinnor polisanmäler händelsen och ännu färre söker medicinsk 
hjälp. I Stockholm är den akuta medicinska vården och omhändertagandet efter våldtäkt 
centraliserad till Akutmottagningen för våldtagna kvinnor (AVK) på Södersjukhuset. 
Mottagningen öppnade 2005 och tar varje år emot mellan 600-700 kvinnor som söker akut 
hjälp efter våldtäkt. Kvinnorna är välkomna inom en månad efter övergreppet och erbjuds 
medicinsk hjälp, rättsmedicinsk undersökning och uppföljande krisstöd.  Den här 
avhandlingen är baserad på studier på just dessa kvinnor. Syftet med avhandlingen var att öka 
kunskapen om kvinnor som söker hjälp efter våldtäkt samt de psykologiska konsekvenserna 
av våldtäkt och påverkan på hjärnan. 
 I det första delarbetet undersökte vi hur kvinnans relation till förövaren påverkar 
förekomsten av fysiskt våld och uppkomst av skador i samband med en våldtäkt. Detta 
gjordes genom att granska journaler och rättsmedicinska undersökningar från 690 kvinnor 
som sökt hjälp under en 13-månadersperiod. Vi fann att de kvinnor som blivit våldtagna av 
en intim partner hade utsatts för grövre fysiskt våld och hade fysiska skador minst lika ofta 
som de kvinnor som blivit våldtagna av en annan för dem bekant förövare eller av en obekant 
(s.k. överfallsvåldtäkt).  
Efter ett allvarligt trauma, i detta fall våldtäkt, finns det en stor risk att de symtom som ofta 
ingår i en akut stressreaktion kvarstår längre än en månad och då övergår i ett 
sjukdomstillstånd som heter posttraumatiskt stressyndrom (PTSD). En person som utvecklar 
PTSD lider av att ständigt återuppleva traumat i form av flashbacks eller mardrömmar, 
undviker saker och situationer som påminner om traumat samt har ett ständigt ökat 
stresspåslag. Dessa symtom påverkar individen så pass kraftigt att de har en handikappande 
effekt och många gånger påverkas individens arbetsförmåga samt förmåga till socialt 
umgänge. Tidigare internationella studier har visat att våldtäkt är ett av de trauman som 
innebär högst risk att insjukna i PTSD och att ungefär 30-40 % av våldtagna kvinnor 
utvecklar PTSD efter händelsen. För att kunna förebygga insjuknande är det viktigt att kunna 
identifiera de kvinnor som lider störst risk att utveckla PTSD. I avhandlingens andra 
delarbete fann vi att 39 % av kvinnorna som sökt på AVK hade utvecklat PTSD efter 6 
månader och att de som hade störst risk att utveckla PTSD var de som utsatts för en 
gruppvåldtäkt, liksom de som hade en kraftig akut stress reaktion efter övergreppet, de som 
utsatts för multipla sexuella handlingar under övergreppet samt ådragit sig skador. Vidare såg 
vi att de som hade en historia av tidigare traumatiska händelser och någon form av tidigare 
psykiatrisk sjuklighet (oftast depression) hade en ökat risk att utveckla PTSD.  
Ett trauma som våldtäkt är en enorm stressituation för kroppen. Vid akut stress vet vi att 
kroppen utsöndrar ett flertal stressteroider från binjurebarken, t.ex. den välkända steroiden 
kortisol. Dessa steroider hjälper till att hantera stressen i kroppen och ser till att 
stressreaktionen stängs av efter att hotet är borta. Vid upprepat eller kroniskt trauma finns 
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dock teorier att kroppens förmåga att utsöndra t.ex. kortisol sänks. Om man inte får detta 
kortisolpåslag har tidigare studier pekat på att risken att utveckla PTSD ökar. Vi ville ta reda 
på om nivån av en viss steroid kan förutse utvecklandet av PTSD efter våldtäkt. Eftersom 
kvinnor söker akut efter våldtäkt under dygnets alla timmar behövde vi också veta om 
nivåerna av steroider varierar under dygnet för att kunna justera för en eventuell 
dygnsvariation av steroiden. Kortisol har en känd dygnsvariation med högst nivåer på 
morgonen strax efter uppvaknandet, dock är det inte helt klart beskrivet i litteraturen hur det 
är för andra steroider t.ex. den stressrelaterade och mycket potenta steroiden allopregnanolon. 
I det tredje delarbetet undersökte vi just detta och fann att de flesta stressrelaterade 
steroiderna har en dygnsvariation liknande kortisol som därför behöver justeras för. I fjärde 
delarbetet fann vi ingen skillnad i koncentrationen av stressrelaterade steroider direkt efter 
våldtäkten mellan de som senare utvecklade PTSD eller inte. Däremot såg vi att de som hade 
upplevt flera tidigare trauman hade sänkta kortisolnivåer direkt efter våldtäkten och att de 
som hade en tidigare psykiatrisk sjuklighet hade lägre allopregnanolonnivåer. Riktigt hur vi 
ska tolka detta vet vi inte men det verkar ändå som om de med tidigare trauman och 
sjuklighet har en ökad känslighet och en påverkad stressrespons. 
Då patienter med PTSD ofta har kraftiga sömnbesvär och ångestsymtom är det viktigt att 
kunna hjälpa och behandla på bästa sätt. Hos andra patientgrupper brukar dessa symtom ofta 
behandlas med s.k. benzodiazepiner, dvs. klassiska sömn- och ångestlindrande tabletter. Då 
det finns beskrivet att dessa läkemedel inte fungerar tillfredställande på patienter med PTSD 
ville vi undersöka detta. Gemensamt för alla benzodiazepiner är att de har sin verkan genom 
att binda till en receptor i hjärnan som heter GABA-A receptorn. Detta är samma receptor 
som t.ex. alkohol binder till och som vi vet leder intag av alkohol i tillräcklig mängd till ökad 
trötthet. Även allopregnanolon, som utsöndras vid stress binder till denna receptor. Ett sätt att 
mäta påverkan på GABA-A receptorn hos en patientgrupp är att mäta ögonrörelsehastigheten 
efter att man gett ett ämne som binder till receptorn. I femte och sista delarbetet fann vi att 
patienter med PTSD var mindre känsliga för benzodiazepiner och allopregnanolon jämfört 
med friska kontroller. PTSD patienterna blev mindre trötta och fick mindre påverkan på 
ögonrörelsehastigheten. Vi har tolkat att detta beror på en toleransutveckling i receptorn pga. 
att PTSD patienter går med ett ständigt stresspåslag och höga nivåer av stressteroider.   
Min konklusion från denna avhandling är att de flesta våldtäkter inte leder till fysiska skador 
men däremot psykiska. Vi såg att intimpartnervåldtäkter innehåller mer våld och resulterar i 
skador minst lika ofta som efter överfallsvåldtäkter. Dock är skadorna oftast i form av 
blåmärken på armar och ben och inte skador i underlivet. PTSD efter våldtäkt är vanligt och 
risken att insjukna ökar genom en kombination av kvinnans sårbarhet och våldtäktens 
allvarlighetsgrad. Vidare kunde vi i vår studie utifrån nivåer på olika stressrelaterade steroider 
inte förutse vilka som skulle utveckla PTSD men däremot såg vi lägre nivåer hos de med 
tidigare trauma och tidigare psykiatrisk sjuklighet. Slutligen, som en konsekvens av GABA-
A receptorns minskade känslighet hos PTSD patienter så har GABA-A receptor aktiva ämnen 
såsom sömntabletter mindre effekt på denna patientgrupp.  
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